ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 1 Investi
gational New Drug 
ALN-PCS SC 
The Orion H oFH Study 
An Open-Label, Single-Arm, Multicenter Pilot Study to Evaluate Safety, Tolerability, and 
Efficac
y of ALN-PCS SC in Subjects with Homozygous Familial Hypercholesterolemia 
Protocol No.:   MDCO -PCS - 16-02 ‚ÄúORION -2‚Äù 
U.S. IND No.: 127589  
EudraCT No.:  2016 -003376 -49 
Amended Protocol Dated : 07 November 2016  
Original Protocol Dated:  02 September 2016  
Development Phase : II 
Sponsor : The Medicines Company  
8 Sylvan Way  
Parsippany, NJ 07054  
Issue Date : Date:  07 November , 2016  
CONFIDENTIAL 
Property of The Medicines Company 
May not be used, divulged, published or otherwise disclosed without the consent of 
The Medicines Company 
This study will be conducted in compliance with Good Clinical Practice (GCP) and protection of the subject 
as required by the regulations and directives in operation at this time. 
$/13&6 6& &OLQLFDO6WXG\3URWRFRO0'&23&6
3URWRFRO$PHQGPHQW 7KH0HGLFLQHV&RPSDQ\
&RQILGHQWLDO 352&('85(6,1&$6(2)(0(5*(1&<
(PHUJHQF\&RQWDFW,QIRUPDWLRQ
5ROHLQ6WXG\ 1DPH 7HOHSKRQH1XPEHU
$/13&6 6& &OLQLFDO6WXG\3URWRFRO0'&23&6
3URWRFRO$PHQGPHQW 7KH0HGLFLQHV&RPSDQ\
&RQILGHQWLDO 35272&2/6<1236,6
1DPHRI6SRQVRU&RPSDQ\ 7KH0HGLFLQHV&RPSDQ\
1DPHRI)LQLVKHG'UXJ $/13&6 6&
1DPHRI$FWLYH,QJUHGLHQW $/1
7LWOHRI6WXG\ $QRSHQODEHOVLQJOHDU PPXOWLFHQWHUSLORWVWXG\WR HYDOXDWHVDIHW\WROHUDELOLW\DQGHIILFDF\RI
$/13&66&LQVXEMHFWVZLWKKRPR]\JRXVIDPLOLDOK\SHUFKROHVWHUROHPLD
3KDVHRI'HYHORSPHQW ,,
6WXG\&HQWHUV 0XOWLFHQWHUVWXG\
&HQWUDO)DFLOLWLHV 0 ,QF
1XPEHURI6XEMHFWV VXEMHFWV
3ULQFLSDO,QYHVWLJDWRU *.HHV+R 3K'0%$
6WXG\3HULRG 7KHHVWLPDWHGVWXG\SHULRGZLOOEHDSSUR[LPDWHO\PRQWKVIU RPILUVWVXEMHFWHQUROOHGLQWKH
VWXG\WRODVWVXEMHFWFRPSOHWHG 
2EMHFWLYHV 
3ULPDU\
7RFKDUDFWHUL]HWKHHIIHFWRI DQGGD\VRIVXEFXWDQHRXV$/13&6 6&RQWKHSHUFHQWDJHFKDQJHIURP 'D\
LQORZGHQVLW\OLSRSURWHLQFKROHVWHURO/'/&LQVXEMHFWVZLWKKRPR] \JRXVIDPLOLDOK\SHUFKROHVWHUROHPLD
6HFRQGDU\ 
¬±7RDVVHVVWKHHIIHFWRI$/13&6 6&RQ
¬± $EVROXWHFKDQJHDQGSHUFHQWDJHFKDQJH LQ/'/&IURP'D\WRHDFKVXEVHTXHQWYLVLWXQWLO 'D\RU
ILQDOYLVLW
¬± $EVROXWHFKDQJH  DQGSHUFHQWDJHFKDQJHLQ3&6.
¬± $EVROXWHFKDQJHDQGSHUFHQWDJ HFKDQJHLQWRWDOFKROHVWHUROWU LJO\FHULGHV+'/&QRQ+'/ &9/'/
&$SR$$SR%DQG/SDIURP' D\WRHDFKVXEVHTXHQWYLVLW XQWLO'D\RUILQDOYLVLW
¬±7RHYDOXDWHWKHVDIHW\DQGWROHUDELOLW\RI$/13&6 6&LQVXEMHFWVZLWKKRPR]\JRXVIDPLOLDO
K\SHUFKROHVWHUROHPLD
([SORUDWRU\ 
¬±7RHYDOXDWHWKHIRUPDWLRQRI$QW LGUXJDQWLERGLHV$'$WR$/1 3&66&
¬±7RDVVHVVUHVSRQVHRI/'/&E\ XQGHUO\LQJFDXVDOPXWDWLRQVRI KRPR]\JRXVIDPLOLDOK\SHUFKROHVWHUROHPLD
+R)+
0HWKRGRORJ\ 
+\SRWKHVHV 7KHSULPDU\K\SRWKHVLVLVWKDW$/13&6 6&ZKHQXVHGLQFRPELQDWLRQZLWK PD[LPDOO\WROHUDWHG
VWDWLQWKHUDS\ZLWKRUZLWKRXWH]HWLPLEH ZLOOEHZHOOWROHUDWHGZLOOVXSSUHVV3&6.V\QWKHVLV DVVHVVHGE\WKH
UHGXFWLRQLQ FLUFXODWLQJ3&6.!DQGZLOOUHVXOWLQUHGXFWLRQRI/'/&G HILQHGDVPHDQSHUFHQWFKDQJH
IURP'D\IROORZLQJGD\VDQGGD \VRIWUHDWPHQWLQVXEMHFWVZ LWKKRPR]\JRXVIDPLOLDO
K\SHUFKROHVWHUROHPLD 
7KLVLVDSLORWVWXG\,IWKHWULDOPHHWVDGHILQHGPHDQ/'/&U HGXFWLRQRI¬ïWKLVZLOOJXLGH WKHGHFLVLRQWR
LQLWLDWHDVXEVHTXHQWODUJHU3KDVH,,,WULDO
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 4 Study Design:   This study  will be a Phase II, open label, single arm, multicenter pilot study in subject s with 
homozygous familial hypercholesterolemia . Informed consent (and verbal assent if subject is < 18 years of age ) 
will be obtained from subjects before the initiation of any study -specific procedures.  
Subjects who meet study inclusion/exclusion criteria will be instructed to continue to follow a NCEP Adult 
Treatment Panel III (or comparable) diet  [Appendix C ] and be required to maintain their current lipid lowering 
drug therapy for the duration of the study.  
In this study, 8 -10 subjects will be enrolled and receive open label ALN -PCS SC 300mg SC. Dosing interval will 
be determined by PCSK9 level at Days 60  or 90 or rate of change of PCSK9 betwee n Days 60 and 90.  
On Day 1, eligible subjects will be enrolled  and receive the first SC administration of ALN -PCS SC. After first 
study drug administration, the subject will be observed in the clinic for at least 4  hours post injection before being 
discharg ed. Subjects will return at day 14  and day 30 and then at monthly intervals . If a second dose of study 
drug is deemed necessary  (depending on the degree of suppression of serum PCSK9 as compared to baseline) , 
subjects will receive this dose  at Day 90 or 104, based on PCSK9 levels from the previous visit . 
Study visits will include  collection of AE and SAE data, vital signs , ECGs , concomitant medication, and 
laboratory tests. See Section  6.1 for a detailed list of assessments. The study also includes collection of biomarker 
(pharmacodynamics)  samples  for efficacy  and, where approved by the independent ethics committee and/or 
institutional review board (IE C/IRB) and applicable regulatory and other authorities, all subjects will be invited to 
consent to pharmacogenetics analyses, unless underlying causal mutations of HoFH are well documented by a 
validated specialized laboratory.   
Efficacy assessments will include measure ment of  the effects of ALN -PCS SC on levels of LDL -C, other 
lipoproteins including total cholesterol (TC), triglycerides, high -density lipoprotein cholesterol (HDL -C), non -
HDL -C, very low -density lipoprotein cholesterol (VLDL -C), apolipoprote in A1 (Apo -A1), apolipoprotein B 
(Apo -B), lipoprotein(a) [Lp(a)], and PCSK9.  
Formation of anti-drug antibodies ( ADA ) will be assessed on Day 1 (prior to and 4 hours after the injection) and 
on subsequent visits until the end-of-study ( EOS) .  
The EOS visit  and the last estimation of lipids will occur at Day 180.  Following Day 180 subjects will continue 
in the study until the observed LDL -C reduction is less than 20% of the absolute reduction from baseline to Day 
90.Subjects will be encouraged to complete all planned visits.  The decision to initiate a Phase III study  will be
defined as an observed mean 15% or greater reduction in LDL -C. A number of factors may influence the 
proportion of subjects achieving this metric, in particular the specific LDL receptor mutation(s) or other causative 
mutations of HoFH  studied. Given the small sample size, such issues will be taken into careful consid eration 
prior to making the final decision.   
The efficacy and safety/ tolerability data from this study will be reviewed by a Safety Committee (SC) on an 
ongoing basis, and the r esults will be used to guide the decision to initiate a phase III study.  A recommendation 
may be taken to stop or amend the study at any of these reviews.  
Diagnosis and Main Criteria for Selection : 
Inclusion Criteria:  
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 5 1.Males and females, ‚â• 12 years of age with a diagnosis of homozygous familial  hypercholesterolemia by
genet ic confirmation or a clinical diagnosis based on a history of an  untreated LDL -C concentration >500
mg/dl (13 mmol/L)  together with either  xanthoma before 10 years of age or evidence of heterozygous
familial hypercholesterolemia in  both parents.
2.Stable on a low -fat diet
3.Stable on their pre -existing, lipid -lowering  therapies (such as statins, cholesterol -absorption inhibitors, bile -
acid sequestrants, or combinations thereof) for at least 4 weeks with no planned medication or dose change
for the dur ation of study participation
4.Fasting central lab LDL -C concentration >130 mg/dl (3.4 mmol/L) and triglyceride concentration < 400
mg/dL (4.5 mmol/L),
5.Bodyweight of 40 kg or greater at screening.
6.Subjects should be willing and able to give written informed consent before initiation of any study -related
procedures (if the subject is less than 18 years of age, written consent will be obtained from their guardian or
legally authorized representative, with verbal assent from the child).
Exclusion crit eria:  
1.LDL or plasma apheresis within 8 weeks prior to the screening visit, and no plan to receive it during the
study because of the attendant difficulty in maintaining stable concentrations of LDL -C while receiving
apheresis.
2.Use of Mipomersen or Lomitapi de therapy within 5 months of screening .
3.Previous treatment with monoclonal antibodies directed towards PCSK9 within 8 weeks of screening .
4.New York Heart Association (NYHA) class III or IV heart failure or last known left ventricular ejection
fraction < 30% or any cardiac arrhythmia within past 3 months that is not controlled by medication .
5.Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass
graft (CABG) or stroke within 3 months of enrollment
6.Planned c ardiac surgery or revascularization
7.Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood pressure >110
mmHg despite anti -hypertensive therapy.
8.Poorly controlled diabetes mellitus, i.e., glycated hemoglobin A1c (HbA1c) >10. 0%.
9.Estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m2
10.Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver
or unexplained alanine aminotransferase (ALT), aspartate aminotransferase (AST) , elevation > 3x the upper
limit of normal (ULN), at screening confirmed by a repeat measurement at least 1 week apart.
11.Creatine kinase (CK) > 5x ULN without a known cause
12.Other s erious comorbid disease in which the life expectancy of the subject is shorter than the duration of the
trial (e.g., acute systemic infection  or other serious illnesses).
13.Any history of malignant disease, with the exception of treated basal -cell carcinoma occurring >5 years
before screening.
14.Females who are pregnant or nursin g, or who are of childbearing potential (includes adolescent females who
have reached menarche and are sexually active) and unwilling to use at least two methods of contraception
(e.g., oral contraceptives, barrier methods, approved contraceptive implant, long- term injectable
contraception, intrauterine device)  for the entire duration of the study . Exemptions from this criterion :
a.Women >2 years postmenopausal (defined as 1 year or longer since their last menstrual period ) AND
more  than 55 years of age
b.Postmenopausal women (as defined above) and less than 55 year s of age with a negative pregnancy test
within 24 hours of enrollment
c.Women who are surgically steril ized at least 3 months prior to enrollment
d.Adolescent females who have not reached menarche
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 6 15.Males who are unwilling to use an acceptable method of birth control during the entire study period ( e.g.,
condom with spermicide).
16.Known history of alcohol and/or drug abuse  within 5 years .
17.Any condition that according to the investigator could interfere w ith the conduct of the study, such as but not
limited to:
a.Inappropriate for this study, including subjects who are unable to communicate or to cooperate with the
investigator.
b.Unable to understand the protocol requirements, instructions and study -related r estrictions, the nature,
scope, and possible consequences of the study (including subjects whose cooperation is doubtful due to
drug abuse or alcohol dependency).
c.Unlikely to comply with the protocol requirements, instructions, and study -related restrictio ns (e.g.,
uncooperative attitude, inability to return for follow -up visits, and improbability of completing the
study).
d.Have any medical or surgical condition, which in the opinion of the investigator would put the subject at
increased risk from participat ing in the study.
e.Involved with, or a relative of, someone directly involved in the conduct of the study.
18.Any clinically significant disease or condition affecting a major organ system, including but not limited to
gastrointestinal, renal, hepatic, endocrinologic, pulmonary, neurological, metabolic or cardiovascular disease.
19.Any surgical or medical condition which, in the judgment of the Investigator, might interfere with the
pharmacokinetics, distribution, metabolism, or excretion of the study drug (if applicable).
20.Treatment with other investigational medicinal products or devices within 30 days or 5 half -lives, whichever
is longer, prior to the administration of the study drug, planned use of investigational medicinal products or
devices.
21.Previous p articipation in this study or any preceding study with ALN -PCS SC.
22.Hypersensitivity to any of the ingredients o f the study drug being used.
Test Drug, Dose and Mode of Administration, Batch Number(s ):  
The study drug  (ALN -PCS SC) will be administered by subcutaneous (SC) injection as a formulation of 
ALN -60212. It will be supplied as a sterile 100 mg vial (200 mg/mL solution) for SC injection.  
ALN -PCS SC will be administered as a single SC in jection of 300mg on Day 1. If mean serum PCSK9 levels are 
not suppressed by > 70% at Day 60 or 90, as compared to baseline , a second dose of 300mg will be administered 
at the next visit at Day 90 or 104 respectively .  
Duration of Treatment : The expected duration of the subjects‚Äô involvement in the study will be approximately 
208 days, which includes screening, study drug administration, and the follow -up period  through EOS . However 
additional follow -up visits may occur every 30 days until Day 300 for subjects whose LDL -C reduction is less 
than 20% of the absolute reduction from baseline to Day 90 (for a maximum duration up to 328 days ). If ALN -
PCS SC is found to be effective in lowering LDL -C in HoFH, a subsequent  study may follow for subjects 
participating in the study.  
Reference Therapy, Dose and Mode of Administration :  There is no reference therapy in this study.  
Criteria for Evaluation :  
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 7 Efficacy :   
Primary Endpoint : Percentage change in LDL -C. 
Secondary Endpoint(s) : 
ÔÇ∑Absolute change and percent age change in LDL -C
ÔÇ∑Absolute c hange  and percent age change in PCSK9 levels
ÔÇ∑Absolute c hange  and percent age change  in other total  cholesterol, triglycerides, HDL -C, non -HDL -C,
VLDL -C, Apo-A1, Apo-B and Lp(a)
Exploratory Endpoint(s) : 
ÔÇ∑Anti-drug antibodies (ADA) to ALN -PCS SC
ÔÇ∑Response of LDL -C reduction by underlying causal mutations of HoFH
Safety :  AEs, SAEs, vital signs, clinical laboratory values (hematology, HbA1c,  coagulation testing, 
biochemistry, high sensitivity C -reactive protein ( hsCRP ), and urinalysis), and electrocardiograms (ECGs) will be 
collected at specified visits through to the EOS visit. In addition, ADA will be evaluated for the study drug . 
Statistical Methods :  
The primary analysis set is the modified Intent -to-Treat set (mITT ), which will include all enrolled subjects who 
have received at least 1 dose of study drug . 
Unless specified otherwise, the mITT will be the default analysis set in this study.  
Summary statistics for continuous variables will include the number of sub jects, mean, median,  standard 
deviation or standard error, minimum and maximum. For categorical variables, the  frequency and percentage will 
be given.  
The primary endpoint is the percent change from Day 1  in LDL -C following 90 and 180 days  of treatment.  
Summary statistics  and 95% CI of this  primary endpoint will be provided. Changes of LDL -C from Day 1  by 
scheduled visits will also  be summarized. Response rate of subjects with 15% or greater reduction in LDL -C from 
Day 1  following 90 and 180 days  of treatment will be calculated.  
Safety summaries will include the incidence of adverse events, summaries of laboratory  parameters, vital signs, 
ECGs and anti -drug antibodies.  
Sample Size 
The sample size was chosen based on clinical considerations. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 8 TABLE OF
 CONTENTS 
1. INTRODUCTION ......................................................................................................15 
1.1. B
ackground .................................................................................................................15 
1.1.1. Dise
ase Overview .......................................................................................................15 
1.1.2. P
CSK9 Biology and Target Rationale ........................................................................15 
1.1.3. Me
chanism of RNA Interference ................................................................................16 
1.2. A
LN-PCS SC, an R NAi Therapeutic for Hypercholesterolemia ..................................17 
1.2.1. Nonclinical Studies .....................................................................................................17 
1.2.2. C
linical Studies ...........................................................................................................18 
1.2.3. Know
n and Potential Risks and Benefits....................................................................19 
1.3. S
tudy Rationale ...........................................................................................................19 
1.4. S
tudy Population .........................................................................................................20 
2. TR
IA L OBJECTIVES AND PURPOSE ....................................................................21 
2.1. Primary Objective(s) ...................................................................................................21 
2.2. S
econdary Objective(s) ...............................................................................................21 
2.3. Ex
ploratory Objective(s) ............................................................................................21 
3. TR
IA L DESIGN .........................................................................................................22 
3.1. Type/Design of Trial ...................................................................................................22 
3.2. S
chematic Diagram of Trial Design ...........................................................................23 
3.3. P
rimary Endpoint ........................................................................................................23 
3.4. S
econdary Endpoint(s) ................................................................................................23 
3.5. Ex
ploratory Endpoint(s) .............................................................................................23 
3.6. Me
asures to Minimize/Avoid Bias .............................................................................23 
3.7. S
afety Committee (SC) ...............................................................................................24 
4. S
UBJECT POPULATION .........................................................................................25 
4.1. Numbe
r of S ubjects ....................................................................................................25 
4.2. Inclusion Criteria ........................................................................................................25 
4.3. Ex
clusion Criteria .......................................................................................................25 
4.4. W
ithdrawal Criteria ....................................................................................................27 
4.4.1. W
ithdrawal from Study Medication ...........................................................................28 
5. TREATMEN
T OF  SUBJECTS ..................................................................................29 
5.1. Study Medication ........................................................................................................29 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 9 5.1.1. ALN-PCS SC ................................ ................................................................................29 
5.1.2. Packaging and Labeling ..............................................................................................29 
5.1.3. S
torage ........................................................................................................................30 
5.1.4. Ac
countability .............................................................................................................30 
5.1.5. P
roduct Complaints ....................................................................................................30 
5.2. C
oncomitant Medications ...........................................................................................31 
5.2.1. R
equired Concomitant Medication(s) and Diet ..........................................................31 
5.2.2. P
rohibited Concomitant Medications .........................................................................31 
5.2.3. P
ermitted Concomitant Medication(s) ........................................................................32 
5.3. Me
dical Management Guidelines ...............................................................................32 
5.4. R
estrictions .................................................................................................................32 
5.5. B
linding ......................................................................................................................32 
6. S
CHEDULE AND SEQUENCE OF PROCEDURES ...............................................33 
6.1. S
chedule of Events/Assessments ................................................................................34 
6.2. Ge
neral Conduct of the Trial ......................................................................................36 
6.3. S
creening Period (Days ‚Äì28 to ‚Äì1) .............................................................................36 
6.4. Enr
ollment (Day 1) .....................................................................................................37 
6.5. F
ollow-up Visits FU 1-6 .............................................................................................38 
6.6. End of
 Stud y (EOS) Visit (FU 7) ...............................................................................38 
6.7. Additional F ollow-Up Visits (FU 8 -11, if needed) ....................................................39 
7. PROTOCOL ASSESSMENTS ..................................................................................40 
7.1. Asse
ssme nt of Safety ..................................................................................................40 
7.1.1. Adverse Events ...........................................................................................................40 
7.1.2. De
mographics and Medical History ...........................................................................40 
7.1.3. Vital S
igns  ..................................................................................................................40 
7.1.4. Electrocardiograms .....................................................................................................40 
7.1.5. P
hysical Examination .................................................................................................40 
7.1.6. C
linical Laboratory Assessments ...............................................................................40 
7.1.7. Anti
-ALN-PCS SC Antibodies .....................................................................................41 
7.2. Assessme nt of Efficacy ...............................................................................................41 
7.2.1. Change in LDL-C .......................................................................................................41 
7.2.2. C
hange in Lipids/Lipoproteins ...................................................................................42 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 10 7.3. Assessme nt of Pharmacogenetics ...............................................................................42 
8. ADVER SE EVENTS..................................................................................................43 
8.1. Definitions ..................................................................................................................43 
8.1.1. Adve
rse Event .............................................................................................................43 
8.1.2. S
erious Adverse Event ................................................................................................43 
8.1.3. Me
dication Errors .......................................................................................................44 
8.2. EV
ALUATING ADVERSE EVENTS .......................................................................44 
8.2.1. AE
 Severity .................................................................................................................44 
8.2.2. S
tudy Drug Causality ..................................................................................................44 
8.2.3. Adve
rse Event of Special Interest (AESIs) ................................................................45 
8.2.4. S
pecial Situations ........................................................................................................45 
8.3. P
ROCEDURE FOR ADVERSE EVENT REPORTING ...........................................46 
8.3.1. P
rocedure for Non-Serious Adverse Event Recording ...............................................46 
8.3.2. P
rocedure for Serious Adverse Event Reporting ........................................................46 
8.3.3. P
rocedure for Medication Error Reporting For Study Drug .......................................46 
8.3.4. P
rocedure For Reporting Adverse Events Of Special Interest (AESIs) .....................46 
8.3.5. P
rocedure For Reporting Pregnancies Exposure ........................................................47 
8.3.6. P
rocedure For Reporting Special Situations ...............................................................47 
9. DA
TA C OLLECTION ...............................................................................................48 
10. STATISTICAL PLAN................................................................................................49 
10.1. Sampl
e S ize ................................................................................................................49 
10.2. Randomization ............................................................................................................49 
10.3. Ge
neral Statistical Considerations and Definitions ....................................................49 
10.3.1. Gene
ral Statistical Methods ........................................................................................49 
10.3.2. Anal
ysis Populations ..................................................................................................49 
10.3.2.1. Modifie
d Intent- to-Treat (mITT) Population ..............................................................49 
10.3.2.2. Sa
fety Population ........................................................................................................50 
10.3.3. Anal
ysis Windows and Baseline ................................................................................50 
10.3.4. Missing
 Data Handling ...............................................................................................50 
10.4. Statistical Analyses .....................................................................................................50 
10.4.1. De
mographic and Background Characteristics ..........................................................50 
10.4.2. Stud
y Drug and Concomitant Medications .................................................................50 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 11 10.4.3. Effic
acy Analysis ........................................................................................................50 
10.4.3.1. Prima
ry Efficacy Endpoint .........................................................................................50 
10.4.3.2. Se
condary Efficacy Endpoints ....................................................................................51  
10.4.3.3. Tertiary Efficacy Endpoints ........................................................................................51 
10.4.4. Sa
fety Analysis ...........................................................................................................51 
10.4.4.1. Adverse
 Events ...........................................................................................................51 
10.4.4.2. Laboratory Tests .........................................................................................................51 
10.4.4.3. Vital Sig
ns ..................................................................................................................51 
11. RECORDS RETENTION ..........................................................................................52 
12. QU
ALITY CONTROL AND QUALITY ASSURANCE .........................................53 
12.1. Moni
toring ..................................................................................................................53 
12.2. Auditi
ng ......................................................................................................................53 
12.3. Protocol Deviations ................................................................ ....................................53 
13. ETHIC S AND RESPONSIBILITY ............................................................................55 
13.1. Informed Consent .......................................................................................................55 
13.2. I
nstitutional Review Board/Ethics Committee ...........................................................55 
14. C
ONFIDENTIALITY ................................................................................................56 
15. I
NVESTIGATOR AGREEME NT ................................ .............................................57 
16. REFERENCES ...........................................................................................................58 
APPEND
IX A.  NEUROLOGICAL EXAMINATION ..............................................................61 
APPEND
IX B.  SAMPSON CRITERIA FOR DIAGNOSING ANAPHYLAX IS .....................65 
APP
END
IX C.  TLC DIET ..........................................................................................................66 
LIST OF TABLES 
Ta
ble 1:  Investigational Product ...............................................................................................29 
Table 2:  C
ommon Terminology Criteria for Adverse Events (CTCAE) of Injection 
Site Reaction ...............................................................................................................45 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 12 LIST OF
 ABBREVIATIONS 
ADA  anti-drug antibodies  
AE adverse event  
AESI  Adverse Event of Special Interest  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
Apo-A1 apolipoprotein A1  
Apo-B apolipoprotein B  
aPTT  activated partial thromboplastin  
ASCVD  atherosclerotic cardiovascular disease  
AST  aspartate aminotransferase  
BUN  total protein urea  
CABG  coronary artery bypass graft  
CHD  coronary heart disease  
CK creatine kinase  
CRP  C-reactive protein  
CTCAE  Common Terminology Criteria for Adverse Events  
CV Cardiovascular  
dL deciliter(s)  
EC Ethics Committee  
ECG  electrocardiogram  
eCRF  Electronic Case  Report Form  
ED50  effective dose of a drug for 50%  of the population receiving the  drug 
ED80  effective dose of a drug for 80% of the population receiving the drug  
EDC  electronic data capture  
eGFR  estimated glomerular filtration rate  
EOS  end of study  
FDA  Food and Drug Administration  
GalNAc  N-acetylgalactosamine  
GCP  Good Clinical Practice  
GGT  gamma glutamyl transferase  
GLP  Good Laboratory Practice  
GPV  Global Pharmacovigilance Department  
HbA1c  glycated hemoglobin A1C  
HDL -C high density lipoprotein  cholesterol  
HoFH  homozygous familial hypercholesterolemia  
hsCRP  high sensitivity C -reactive protein  
IB Investigator‚Äôs Brochure  
IC50  concentration of the drug required for 50% inhibition in vitro  
ICH International Conference on Harmonisation of Technical 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 13 Requirements for Registration of Pharmaceuticals  
IEC Independent Ethics Committee  
IFN-Œ≥ interferon -gamma  
IL6 interleukin 6  
INR International normalized ratio  
IRB Institutional Review Board  
ISR Injection site reaction  
ITT intent -to-treat 
kg kilograms(s)  
LDL -C low density lipoprotein cholesterol  
LDLR  low density lipoprotein receptor  
LNP  lipid nanoparticles  
LP(a)  lipoprotein a  
MCH  mean cell hemoglobin  
MCHC  mean corpuscular hemoglobin concentration  
MCV  mean corpuscular volume  
MD multiple dose  
MDCO  The Medicines Company  
MedDRA  Medical Dictionary for Regulatory Activities  
mg milligram(s)  
MI myocardial infarction  
mITT  Modified intent -to-treat 
mL milliliter(s)  
mm millimeter(s)  
mmHg  millimeters of mercury  
mmol  Millimole  
mRNA  messenger ribonucleic acid  
NCEP  National Cholesterol Education Progra m 
NHP  nonhuman primate  
NOAEL  no observed adverse effect level  
NYHA  New York Heart Association  
PCI percuta neous coronary intervention  
PCS potentially clinical significant  
PCSK9  proprotein convertase subtilisin/kexin type 9  
pH -log[H+]  
PT prothrombin time  
RBC  red blood cells  
RNA  ribonucleic acid  
RNAi  ribonucleic acid interference  
SAD  single ascending dose  
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 14 SAE  serious adverse event  
SAP Statistical Analysis Plan  
SC Safety  Committee , subcutaneous  
SD standard deviation  
siRNA  small interfering ribonucleic acid  
TBIL  total bilirubin  
TC total cholesterol  
TEAE  treatment emergent adverse event  
TNF -Œ± tumor necrosis factor -alpha  
TTR  Target transthyretin  
ULN  upper limit of normal  
USA  United States of America  
VLDL -C very low density lipoprotein  cholesterol  
WBC  white blood count  
WHO  World Health Organization  
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 15 1. INTR
ODUCTION 
This protocol describes a study to assess the safety, tolerability and efficacy of ALN-PCS SC in 
subjec
ts with homozygous familial hypercholesterolemia (HoFH). 
This study
 will be conducted in compliance with Good Clinical Practices (GCP) including the 
Declaration of Helsinki and all applicable regulatory requirements. 
1.1. Background 
1.1.1. Disease Overview 
Acc
ording to the World Health Organization (WHO), atherosclerotic cardiovascular disease 
(ASCVD), comprised mainly of coronary heart disease (CHD) and stroke, is the leading cause of 
death worldwide, resulting in 17 million deaths annually [ WHO Cardiovascular Statistics, 2011 ]. 
Data from the INTERHEART case-control study estimates that 45% of myocardial infarctions 
(MI) in Western Europe and 35% of myocardial infarctions in Central and Eastern Europe are 
due to abnormalities in blood lipids [ Yusef et al, 2004 ]. In particular, elevated LDL-C has been 
shown in mult
iple studies to be one of the major risk factors for CHD with a continuous and 
graded relationship between plasma LDL-C concentration and CHD risk. For every 30 mg/dL 
(0.78 mmol/L) change in LDL-C, the relative risk for CHD changes by approximately 30% 
[Grundy
 et al, 2004]. In addition, a large meta-analysis of 21 statin studies concluded that for 
ever
y 1 mmol/L (39 mg/dL) reduction in LDL-C (with statin therapy) there is an approximate 
22% reduc
tion in cardiovascular events [ CTTC et al, 2010] . While statins are the treatment of 
choice for hyperlipidemia and the primary and secondary prevention of ASCVD there is still a 
need for additional lipid-lowering therapies for patients who do not reach target L DL-C levels or 
sufficient percent reductions in LDL-C to attenuate their ASCVD risk. Furthermore, in many 
patients, statin therapy cannot be optimized as patients are either intolerant of statins due to side 
effects (most commonly muscle pain, myopathy myositis) or because of other adverse effects 
such as elevations in liver enzymes. These limitations of contemporary therapy are particularly 
relevant among patients with pre-existing ASCVD such as diabetes, or patients with familial 
hypercholesterolemia who are at the highest risk of future cardiovascular (CV) events, and hence 
require the most intensive and aggressive management of hypercholesterolemia [ Davidson et al, 
2005; Nag et al, 2007; Reiner et al, 2011; Stone et al, 2014] . Among these high-risk subjects, less 
than 50% achieved the target LDL-C goal of <100 mg/dL at 6 months post-statin treatment 
despite close monitoring and drug regimen optimization [ Foley et al, 2003; Kearney et al, 2008; 
CTTC et al, 2010; Foody et al, 2010 ]. Thus, there remains a clear unmet medical need for 
lowering LDL-C, especially in certain patient populations.  
1.1.2. PCSK9 Biology and Target Rationale 
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a member of the subtilisin serine 
protease family. Proprotein convertase subtilisin kexin type 9 is predominantly expressed by the 
liver and is critical for the down regulation of hepatocyte low-density lipoprotein receptor 
(LDLR) expression [ Mousavi et al, 2009 ]. LDL-C levels in plasma are markedly elevated in 
humans with gain of function mutations in PCSK9, classifying them as having severe familial 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 16 hype
rcholesterolemia [ Abifadel et al, 2003 ]. Data from genetic association studies have 
identified loss of function alleles in human PCSK9 that result in lower PCSK9 protein levels and 
lower LDL-C levels [Zhao et al, 2006 ; Hooper et al, 2007 ; Horton et al, 2009 ]. In one published 
study, heterozygous individuals (carrying a single copy of a loss of function PCSK9 mutation) 
had significantly lower LDL-C with median levels of approximately 70 mg/dL (1.81 mmol/L) 
[Cohen e
t al, 2006 ]. Over a 15-year period of retrospective data analysis, this sustained lowering 
in LDL-C levels translated to an 88% lower risk of risk for CHD. Follow-up publications 
describe two adult individuals who are compound heterozygous for loss of function alleles of 
PCS
K9. These individuals lack detectable plasma PCSK9 protein, have LDL-C levels ‚â§20 
mg/dL, and yet are otherwise healthy [ Zhao et al, 2006 ; Hooper et al, 2007 ]. Additionally, recent 
human clinical trials with PCSK9 blocking antibodies have shown significant lowering of LDL-
C in healthy volunteers and across a range of high CV risk populations and with elevated LDL- C 
both with and without statins [ Banerjee et al, 2012 ; Dias et al, 2012; Milazzo et al, 2012 ; Raal et 
al, 2012 ; Roth et al, 2012 ; Stein et al, 2012 ; Sullivan et al, 2012 ; Hooper et al, 2013 ]. Thus, the 
overa
ll scientific and clinical data suggests that PCSK9 is a well-validated drug target whose 
inhibition results in significant LDL-C lowering without otherwise negatively impacting overall 
health, most recently culminating in the approval of two monoclonal agents to inhibit PCSK9. 
1.1.3. Mechanism of RNA Interference 
Ribonucle
ic acid (RNA) interference (RNAi) is a naturally occurring cellular mechanism for 
regulating gene expression that is mediated by small interfering RNAs (siRNAs). Typically, 
synthetic siRNAs are 19-base to 25-base pair double-stranded oligonucleotides in a staggered 
duplex with a two-
 to four-nucleotide overhang at one or both of the 3‚Äô ends. Such siRNAs can 
be desig
ned to target an endogenous messenger RNA (mRNA) transcript of a given gene. When 
introduced into cells, the guide (or antisense) strand of the siRNA loads into an enzyme complex 
called the RNA-Induced Silencing Complex. This enzyme complex subsequently binds to its 
complementary mRNA sequence, mediating cleavage of the target mRNA and the suppression of 
the target protein encoded by the mRNA [ Elbashir et al, 2001 ].  
Since unmodified siRNAs are rapidly eliminated and do not achieve significant tissue 
distribution upon systemic administration [ Soutschek et al, 2004 ], various formulations are 
currently used to target their distribution to tissues, and to facilitate uptake of siRNAs into the 
relevant cell type. One approach that has been used successfully in vivo, in animal models 
(including in rodents and nonhuman primates [NHP]) and humans employs intravenous delivery 
of siRNA in lipid nanoparticle (LNP) formulations [ Soutschek et al, 2004 ; Morrissey et al, 2005 ; 
Geisbert et al, 2006 ; Judge et al, 2006 ; Zimmermann et al, 2006 ; Coelho et al, 2013 ; Tabernero 
et al, 2013]. Another approach for liver-specific gene silencing is subcutaneously administered 
siRNA conjugated to a N-acetylgalactosamine (GalNAc) carbohydrate ligand [ Ashwell and 
Morell, 1974 ]. Conjugation of a triantennary GalNAc ligand to an siRNA enables hepatocyte 
binding and subsequent cellular uptake via the asialoglycoprotein receptor, resulting in 
engagement of the RNAi pathway and down regulation of hepatic proteins. Single and multiple 
doses of subcutaneously administered siRNA-GalNAc conjugates have been used to target 
transthyretin (TTR) mRNA for the treatment of TTR-mediated amyloidosis. ALN-TTRCSC has 
been found to be generally safe and well tolerated in Phase I and Phase II clinical trials in over 
40 healthy volunteers and 18 subjects with familial amyloidotic cardiomyopathy and senile 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 17 systemic a
myloidosis ( ALN-TTRSC-001; EudraCT 2012-004203-12 ; and ALN-TTRSC-002; 
EudraC
T 2013-002856- 33).  
1.2. ALN-PCS SC, an R
NAi Therapeutic for Hypercholesterolemia 
ALN-PCS SC Solution for Injection (subcutaneous [SC] use) is comprised of the PCSK9 siRNA, 
ALN
-60212, formulated in phosphate buffer. The PCSK9 siRNA is a chemically synthesized 
double stranded oligonucleotide covalently linked to a ligand containing GalNAc residues. This 
synthetic investigational RNAi therapeutic has been designed to suppress the liver production of 
PCSK9 when administered via SC injection. Inhibition of PCSK9 synthesis through an RNAi 
mechanism has the potential to lower tissue and circulating plasma PCSK9 protein levels, 
resulting in higher expression of LDLR in the liver, and consequently lower LDL-C levels in the 
blood stream. The initial proposed indication for ALN-PCS SC is the treatment of subjects with 
hype
rcholesterolemia who are not achieving therapeutic LDL-C goals despite maximally 
tolerated lipid-lowering therapy, or for subjects who are intolerant of statins. 
1.2.1. Nonclinical Stud ies 
The safety pharmacology and toxicology of ALN- PCS SC was evaluated in a series of in vitro 
and in vivo nonc
linical studies. 
The drug substance in ALN-PCS SC (ALN-60212) is designed to match the human and 
cynomol
gous monkey mRNA transcripts for PCSK9, sharing a substantial partial match to the 
rat PCSK9 mRNA. ALN-60212 was informatically identified from a large collection of possible 
siRNAs tar
geting PCSK9 based on its predicted potency and selectivity. ALN-PCS SC reduced 
the expre
ssion of PCSK9 in Hep3B liver cells with an IC 50 of 20pM and inhibited hPCSK9 
serum protein levels in a Tg mouse model with a single dose ED 50 of approximately 2 mg/kg and 
an ED 80 dose of a
pproximately 6 mg/kg. In single and multi-dose regimen studies in cynomolgus 
monkeys, A
LN-PCS SC exhibited dose-dependent sustainable suppression of PCSK9 protein that 
was par
alleled by lowering of serum LDL-C with the same kinetics. The time to reach PCSK9 
and LDL-C nadir was approximately 20 days and t here was no difference in time to nadir between 
different dose levels.  In single dose studies the maximal mean PCSK9 and LDL-C inhibition was 
85% and 68%, respectively, which was observed at the two highest doses of ALN-PCS SC
administered (6 and 10 mg/kg); however, the duration of PCSK9 silencing and LDL-C lowering 
was markedly extended at the higher 10 mg/kg dose. In mu lti-dose studies the maximal mean 
PCSK9 and LDL-C inhibition was 93% and 74%, respectively, which was similar to those 
observed in the single dose study. Following discontinuation of ALN-PCS SC administration, 
recove
ry of PCSK9 levels was slow, returning to baseline after 100 days in the single dose study 
and only showing partial recovery between doses in the multi-dose regimen. There were no 
ALN
-PCS SC related changes to the levels of HDL-C or triglycerides in any of the groups.  As 
expe
cted, total cholesterol levels were reduced by up to 30% reflecting the decrease in LDL- C. 
Good Laboratory Practice (GLP) compliant repeat dose studies of 4 and 15 weeks duration have 
been c
onducted in rats and monkeys. These studies included toxicokinetic analysis of ALN-
PCS SC in plasma and in tissues including the liver which is the target organ, and the kidney 
which is the
 main organ of elimination.  
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 18 The GL
P 4 week toxicology studies in rats and monkeys involved every other week 
administration of ALN-PCS SC at dose levels of 10, 50 and 250 mg/kg and once a week 
administration of 10 mg/kg for rats and 30 mg/kg for monkeys. The GLP 15 week toxicology 
studies in rats and monkeys involved once monthly administration of ALN-PCS SC at dose levels 
of 10, 50 and 250 m
g/kg and once every other week administration of 125 mg/kg for rats and 25 
mg/kg for monkeys. Each toxicology study also included an 8 week treatment free recovery 
period for all dose groups. ALN-PCS SC was well tolerated in all studies and there were no dose 
limiti
ng toxicities. The most common findings were related to the pharmacological effects of 
ALN-PCS SC on lipid profiles. There were consistent decreases in low density lipoprotein 
cholesterol (
LDL-C) and total cholesterol which were expected. Histopathological findings 
included vac
uolation in hepatocytes of rats and lymph node macrophages of monkeys and the 
presence of basophilic granules in hepatocytes of monkeys and kidneys of rats. These 
microscopic findings were not associated with changes in clinical pathology parameters and are 
consistent wit
h class effects of oligonucleotides and were not considered adverse. In a non-GLP 
dose ran
ge finding (DRF) study conducted in monkeys, ALN-PCS SC did not stimulate pro-
inflamma
tory cytokines, activate complement or impact coagulation. ALN-PCS SC also did not 
stimula
te pro-inflammatory cytokines following single dose administration to mice. In a 
cardiovascular and respiratory study in telemetered conscious cynomolgus monkeys ALN-PCS SC 
had no immediate or delayed effects on clinical observations, qualitative or quantitative ECG 
parameters, hemodynamic parameters, respiration rate, or body temperature at any dose level. In 
addition, ALN-PCS SC did not induce gene mutations or chromosomal damage in a battery of in 
vitro and in vi
vo genotoxicity studies. 
Further information is in the Investigator‚Äôs Brochure (IB). 
1.2.2. Clinical Studies 
One P
hase I study has been conducted to date (Study ALN-PCS SC -001). This was a randomized, 
single-
blind, placebo-controlled, single-dose escalation and multiple-dose study of ALN-PCS SC 
administered SC to subjects with elevated LDL-C. The study was conducted in two phases: a 
single ascending dose (SAD) phase and a multiple dose (MD) phase. During the SAD phase, 
24 subjects were assigned to either receive placebo or one of five doses of ALN-PCS ranging 
from 25 mg
 to 800 mg. Those who received doses of at least 100 mg saw their LDL-C drop at 
least 40%; at the 500 mg
 dose, LDL-C levels dropped as much as 78%. At 140 days after the 
treatment was given, subjects still had an average LDL-C reduction of about 40%. 
In the MD pha
se, 45 subjects received multiple doses of either ALN-PCS (125mg weekly x4, 
250 mg bi-
weekly x2, 300 mg and 500 mg  twice given 1 month apart) or placebo. These subjects 
had maxim
al LDL-C reductions of 80% and average LDL-C reductions of 50% to 60%. To date, 
the drug appears to be generally safe and well tolerated. One subject on statin comedication had 
elevated liver enzymes with ALT >4x the upper limit of normal (ULN), which resolved on 
stopping the statin. 
One Phase II dose finding study (MDCO-PCS-15-01) is currently ongoing. This study is a 
placebo-controlled, double-blind, randomized trial to compare the effect of different doses of 
ALN-P
CSSC given as single or multiple subcutaneous injections in subjects with high 
cardiovascular risk and elevated low-density lipoprotein cholesterol (LDL-C). Randomization 
has been completed and follow up is ongoing. An interim analysis will be performed after all 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 19 patie
nts have completed the Day 90 visit in order to select the dose for subsequent studies. A 
regular review of safety is performed by an independent Data Monitoring Committee and to date 
no safety concerns have been reported and no changes to the protocol have been requested. 
1.2.3. Known and Potential Risks and Benefits 
Subjec
ts taking part in this clinical study will receive guideline recommended standard of care as 
background therapy (including maximally-tolerated statin therapy and/or other LDL-C lowering 
therapies ) when administered ALN-PCS SC. Reduction of LDL-C has been associated with 
reduced CV risk both by epidemiology and in controlled clinical trials. The safety profile 
observed to date is considered acceptable for this clinical trial. 
An expanded risk-benefit summary is provided in the IB. 
1.3. Study Rationale 
Homozygous Familial Hypercholesterolemia (HoFH) is a rare and life-threatening disease 
characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol 
(LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD). The first 
major CV events often occur during adolescence, although angina pectoris, myocardial infarction 
and death have been reported in early childhood. Historically thought to affect one in a million, 
new research indicates that HoFH prevalence is likely to be higher, with as many as one in 
160,000 to 300,000 people affected. There may be as many as 40,000 people world-wide with 
HoFH. Due to the severity of the condition, early diagnosis and initiation of lipid-lowering 
treatment is critical. However, even at the highest doses of the most efficacious statins, only 
modest reductions in LDL C plasma levels, of 10-25%, are observed. Combination of statin plus 
ezetimibe can produce a further decrease in LDL-C levels of 10-15%. Combination with other 
lipid-lowering treatments such as ALN- PCS SC may therefore provide an important adjunctive 
therap
y in HoFH [ Cuchel et al 2014 ]. 
Previous
 studies using PCSK9-targeting siRNAs formulated in LNPs (ALN-PCS02) or using 
PCSK9 antibodies, and one Phase I study with ALN-PCS SC in which subjects received single-
doses asc
ending from 25 mg to 800 mg, have demonstrated that substantial lowering of PCSK9 
is safe and well-tolerated in humans. Doses for the Phase I study were calculated using the rat 
and monkey NOAELs based on body weight and body surface area (mg/m2). Collectively, the 
results of nonclinical studies with ALN-PCS SC supported a starting dose of 25 mg for subjects 
participating
 in the SAD phase of the previous Phase I study. 
In Phase I Study ALN-PCS SC-001, clinically significant reductions in LDL-C levels were seen 
with single 
ALN-PCS SC doses as low as 25 mg with larger decreases seen with higher doses and 
a plateau at 300 mg. Subjects at ALN-PCS SC doses of 300 mg or higher had maximal LDL- C 
reducti
ons of up to 78.1% and average least squares mean group nadir reductions of 50 to 59%. 
In the MD phase, 45 subjects received multiple doses of either ALN-PCS (125 mg weekly x4, 
250 mg biweekly, 300 mg and 500 mg twice given 1 month apart)  or placebo. Subjects at ALN- 
PCS SC dose
s of 300 mg or higher had maximal LDL-C reductions of 83% and average least 
squares mea
n group nadir LDL-C reductions of 53.4% to 59.9 % at all dose levels tested.   
Based on the interim results of the Phase I Study ALN-PCS SC -001, where maximum effect on 
LDL
-C was seen by 84 days and a significant effect was still observed at 180 days, this study has 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 20 been de
signed to test the efficacy and duration of effect of 300mg of ALN- PCS SC  in subjects 
with HoFH. This wi
ll allow dose selection for a subsequent Phase III study in HoFH. The dosing 
regim
ens used in this study are therefore fully supported by the findings of the Phase I study. 
1.4. Study P
opulation 
This study will enroll male and female subjects, ‚â• 12 years of age with a diagnosis of 
homozyg
ous familial hypercholesterolemia. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 21 2. TRIA
L OBJECTIVES AND PURPOSE 
2.1. Primary Objective(s) 
To characterize the effect of 90 and 180 days of subcutaneous ALN-PCS SC on the percentage 
change from Day 1 in low-density lipoprotein cholesterol (LDL-C) in subjects with homozygous 
famili
al hypercholesterolemia 
2.2. Secondary Objective(s) 
ÔÇ∑To assess the effect of ALN-PCS SC on:
ÔÄ≠ Absolute 
change and percentage change in LDL- C from Day 1 to each subsequent
visit until Day 180 or final visit 
ÔÄ≠ Absolute change and percentage change in PCSK9 
ÔÄ≠ Absolute change and percentage change in total cholesterol, triglycerides, HDL-
C, non-
HDL-C, VLDL-C, Apo-A1 Apo- B and Lp(a) from Day 1 to each 
subsequent visit until Day 180 or final visit 
ÔÇ∑To evaluate
 the safety and tolerability of ALN-PCS SC in subjects with homozygous
famili
al hypercholesterolemia
2.3. Exploratory Objective(s) 
ÔÇ∑To evaluate the formation of Anti-drug antibodies (ADA) to ALN-PCS SC
ÔÇ∑To assess response of LDL-C by underlying causal mutations of HoFH
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 22 3. TRIA
L DESIGN 
3.1. Type/Design of Trial 
This study will be a Phase II, open label, single arm, multicenter pilot study in subjects with 
homozyg
ous familial hypercholesterolemia.  Informed consent (and verbal assent if subject is 
< 18 y
ears of age) will be obtained from subjects before the initiation of any study-specific 
procedures.   
Subjec
ts who meet study  inclusion/exclusion criteria will be instructed to continue to follow a 
National Cholesterol Education Program (NCEP) Adult Treatment Panel III (or comparable) diet 
[Appendix C ] and will be required to maintain their current lipid lowering drug therapy for the 
duration of
 the study. 
In this study, 8-10 subjects will be enroll ed and receive open label ALN-PCS SC 300mg SC. 
Dosing int
erval will be determined by PCSK9 level at Day 60 or 90 or rate of change of PCSK9 
betwee
n Days 60 and 90.  
On Day 1, eli
gible subjects will be enrolled and receive the first SC administration of ALN-
PCS SC. Af
ter first study drug administration, the subject will be observed in the clinic for at least 
4 hours post injection before being discharged. Subjects will return at Day 14 and Day 30  and 
then at m
onthly intervals. If a second dose of study drug is deemed necessary (if mean serum 
PCSK9 levels are not suppressed by > 70% at Day 60 or 90, as compared to baseline), subjects 
will rec
eive this dose at Day 90 or 104 respectively, based on PCSK9 levels from the previous 
visit. 
Study
 visits will include collection of AE and SAE data, vital signs, ECGs, concomitant 
medication, and laboratory tests. See Sec tion 6.1 for a detailed list of assessments. The study also 
includes coll
ection of biomarker samples and, where approved by the independent ethics 
committee and/or institutional review board (IEC/IRB) and applicable regulatory and other 
authorities, all subjects will be invited to consent to pharmacogenetics analyses, unless 
underlying causal  mutations of HoFH are well documented by a validated specialized  laborator y.  
Efficacy assessments will include measurement of the effects of ALN- PCSSC on levels of LDL-
C, other li
poproteins including total cholesterol (TC), triglycerides, high-density lipoprotein 
cholesterol (HDL-C), non-HDL-C, very low-density lipoprotein cholesterol (VLDL-C), 
apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), lipoprotein(a) [Lp(a)], and PCSK9.  
Formation of anti-drug antibodies ( ADA) will be assessed on Day 1 (prior to and 4 hours after 
the injection) and on subsequent visits until the end-of-study (EOS).  
The EOS
 visit and the last estimation of lipids will occur at Day 180. Following Day 180 
subjects will continue in the study until the observed LDL-C reduction is less than 20% of the 
absolute reduction from baseline to Day 90. Subjects will be encouraged to complete all planned 
visits.  
The decision to initiate a Phase III study  will be defined as an observed mean 15% or greater 
reduction in LDL-C. A number of factors may influence the proportion of subjects achieving this 
metric, in partic
ular the specific LDL receptor mutation(s) or other causative mutations of HoFH 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02 
The Medicine
s Company 
Confidential 23 studied. Give
n the small sample size for this part of the study, such issues will be taken into 
careful consideration prior to making the final decision.  
The eff
icacy and safety/ tolerability data from this study will be reviewed by a Safety Committee 
(SC) on an ongoing basis, and the results will be used to guide the decision to initiate a Phase III 
study. A r
ecommendation may be taken to stop or amend the study at any of these reviews. 
3.2. Schematic Diagram of Trial Design 
3.3. Primary Endpoint  
The primary endpoint of this trial is percentage change in LDL-C. 
3.4. Secondary Endpoint(s)  
The secondary endpoints of this trial are: 
ÔÇ∑Absolute change and percentage change in LDL- C
ÔÇ∑Absolute change and percentage change in PCSK9 levels
ÔÇ∑Absolute change and percentage change in  total cholesterol, triglycerides, HDL-C,
non-HDL-C, VLDL-C, Apo- A1, Apo-B , and Lp(a)
3.5. Exp
loratory Endpoint(s)  
The exploratory endpoints of this trial are: 
ÔÇ∑Anti-drug antibodies (ADA) to ALN-PCS SC
ÔÇ∑Response of LDL- C reduction by underlying causal mutations of  HoFH
3.6. Measures to Minimize/Avoid Bias  
This is an unblinded, open label study.  The primary endpoint is based on an assessment of LDL-
C, which is a me
asurement that is not likely to be subject to interpretation bias.    

ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 24 3.7. Safet
y Committee (SC) 
A Safety Committee (SC ) will review efficacy and safety data and serious adverse events on an 
ongoing
 basis, and the results will be used to guide the decision to initiate a Phase III study. A 
recommendation may be taken to stop or amend the study at any of these reviews. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 25 4. SUBJEC
T POPULATION 
4.1. Number of Subjects  
In this study, 8-10 subjects will be enrolled at 2-5 multi-national centers. 
4.2. Inc
lusion Criteria 
Subjects may be included in the study if they meet all of the following criteria: 
1. Males and females, ‚â• 12 years of age with a diagnosis of homozygous familial
hypercholesterolemia by genetic confirmation or a clinical diagnosis based on a history of
an untreated LDL-C concentration >500 mg/dl (13 mmol/L)  together with either
xanthoma before 10 years of age or evidence of heterozygous familial
hypercholesterolemia in both parents.
2. Stable on a low-fat diet.
3. Stable on their pre-existing, lipid-lowering therapies (such as statins, cholesterol-
absorption inhibitors, bile-acid sequestrants, or combinations thereof) for at least 4 weeks
with no planned medica
tion or dose change for the duration of study participation.
4. Fasting central lab LDL-C concentration >130 mg/dl (3.4 mmol/L) and triglyceride
concentration < 400 mg/dL (4.5 mmol/L).
5. Bodyweight of 40 kg or greater at screening.
6. Subjects should be willing and able to give written informed consent before initiation of
any
 study-related procedures (if the subject is less than 18 years of age, written consent
will be obtained from their guardian or legally authorized representative, with verbal
assent from the child). The subject should be willing to comply with all required study
procedures.
4.3. Exclusion Criteria 
Subjects will be excluded from the study if any of the following exclusion criteria apply prior to 
enrollment: 
1. LDL or plasma apheresis within 8 weeks prior to the screening visit, and no plan to
receive it during the study because of the attendant difficulty in maintaining stable
concentrations of LDL-C while receiving apheresis.
2. Use of Mipomersen or Lomitapide therapy within 5 months of screening.
3. Pre
vious treatment with monoclonal antibodies directed towards PCSK9 within 8 weeks
of screening.
4. New York Heart Association (NYHA ) class III or IV heart failure or last known left
ventricular ejection fraction < 30% or any cardiac arrhythmia within past 3 months that is
not controlled by medication.
5. Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI),
coronary artery bypass graft (CABG) or stroke within 3 months of enrollment.
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 26 6. Planne
d cardiac surgery or revascularization.
7. Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood
pressure >110 mmHg prior to enrollment despite anti-hypertensive therapy.
8. Poorly controlled diabetes mellitus, i.e., glycated hemoglobin A1c (HbA1c) >10.0% prior
to enrollment.
9. Estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m2.
10. Active liver disease defined as any known current infectious, neoplastic, or metabolic
pathology of the liver or unexplained alanine aminotransferase (ALT), aspartate
aminotransferase (AST), elevation > 3x the upper limit of normal (ULN), at screening
confirmed by a repeat measurement at least 1 week apart.
11. Creatine kinase (CK) > 5x ULN without a known cause.
12. Other serious comorbid disease in which the life expectancy of the subject is shorter than
the duration of the trial (e.g., acute systemic infection, or other serious illnesses).
13. Any history of malignant disease,  with the exception of treated basal-cell carcinoma
occurring >5 years before screening.
14. Females who are pregnant or nursing, or who are of childbearing potential (includes
adolescent females who have reached menarche and are sexually active) and unwilling to
use at l
east two methods of contraception (e.g., oral contraceptives, barrier methods,
approve
d contraceptive implant, long- term injectable contraception, intrauterine device )
for the enti
re duration of the study. Exemptions from this criterion:
a.Women >2 
years postmenopausal (defined as 1 year or long er since their last
menstrual period
) AND more than 55 years of age
b. Postm
enopausal women (as defined above) and less than 55 years old with a negative
pregna
ncy test within 24 hours of enrollment
c.Women who are surgically sterilized at least 3 months prior to enrollment
d. Adolescent females who have not reached menarche
15. Males who are unwilling to use an acceptable method of birth control during the entire
study period (e.g., condom with spermicide).
16. Known history of alcohol and/or drug abuse within 5 years.
17.Any condition that according to the investigator could interfere with the conduct of the
study, such as but not limited to:
a.Inappropriate for this study, including subjects who are unable to communicate or to
cooperate with the investigator.
b. Unable to understand the protocol requirements, instructions and study-related
restrictions, the nature, scope, and possible consequences of the study (including
subjects whose cooperation is doubtful due to drug abuse or alcohol dependency).
c.Unlikely to comply with the protocol requirements, instructions, and study-related
restrictions (e.g., uncooperative attitude, inability to return for follow-up visits, and
improbability of completing the study).
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 27 d. Have
 any medical or surgical condition, which in the opinion of the investigator
would put the subject at increased risk from participating in the study.
e.Involved with, or a relative of, someone directly involved in the conduct of the study.
18. Any clinically significant disease or condition affecting a major organ system, including
but not limited to gastrointestinal, renal, hepatic, endocrinologic, pulmonary,
neurological, metabolic or cardiovascular disease.
19. Any surgical or medical condition which, in the judgment of the Investigator, might
interfere with the pharmacokinetics, distribution, metabolism, or excretion of the study
drug (if applicable).
20. Treatment with other investigational medicinal products or devices within 30 days or 5
half-lives, whichever is longer, prior to the administration of the study drug/device,
planned use of investigational medicinal products or devices.
21. Pre
vious participation in this study or any preceding study with ALN-PCS SC.
22. Hypersensitivity to any of the ingredients of the study drug being used.
Subjects excluded for any of the above reasons may not be re-screened for participation at any 
time if the e
xclusion characteristic has changed. 
4.4. Withdrawal Criteria 
All subjects have the right to withdraw at any point during treatment without prejudice.  The 
investigator can discontinue any subject at any time if medically necessary. It will be 
documented whether or not each subject completed the clinical study. If for any subject study 
treatment or observations were discontinued, the reason will be recorded and the Sponsor should 
be notified promptly. Reasons that a subject may discontinue participation in a clinical study are 
considered to constitute one of the following: 
ÔÇ∑Adverse event(s)
ÔÇ∑Death
ÔÇ∑Subject withdrew consent
ÔÇ∑Physician decision
ÔÇ∑Lost to follow-up
Upon occurrence of a serious or intolerable AE, the investigator or designee will make every 
possible attempt to confer with the Sponsor and the SC before discontinuing the subject. 
It is imperative to obtain complete follow-up data for all subjects whether or not they receive 
their study treatment or have discontinued ALN-PCS SC. All data coll ected up until the time of 
subject withdrawal is to be entered into the electronic case report form (eCRF).  In addition, 
every attempt should be made to collect follow-up information except for those subjects who 
specifically withdraw consent to release of such information.  All procedures and laboratory 
specimens or tests requested for evaluation following administration of ALN-PCS SC should be 
carried out when possible whether or not a subject continues to receive treatment according the 
protocol. Subjects will not be replaced in this trial. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 28 4.4.1. Withdrawal from Study Medication 
In the 
event a subject withdraws or is withdrawn from the study medication (eg, receives first 
injection and not second injection if indicated), the investigator will inform the Medical Monitor 
and the Sponsor immedia
tely. If there is a medical reason for withdrawal, the subject will remain 
under the supervision of the investigator for protocol-specified safety follow up procedures. The 
SC may be notified.  
It is imperative to obtain complete follow-up data for all enrolled subjects whether or not they 
rece
ive their treatment or have discontinued study drug. 
$/13&6 6& &OLQLFDO6WXG\3URWRFRO0'&23&6
3URWRFRO$PHQGPHQW 7KH0HGLFLQHV&RPSDQ\
&RQILGHQWLDO 75($70(172)68%-(&76
6WXG\0HGLFDWLRQ
$/13&6 6&
$/13&6 6&LVDV\QWKHWLFFKHPLFDOO\ PRGLILHGVPDOOLQWHUIHULQJULERQXFO HLFDFLGVL51$
WDUJHWLQJSURSURWHLQFRQYHUWDVH VXEWLOLVLQNH[LQW\SH3&6. PHVVHQJHUULERQXFOHLFDFLG
P51$>$/1@ZLWKDFRYDOHQWO\DWWDFKHGWULDQWHQQDU\1DF HW\OJDODFWRVDPLQH*DO1$F
OLJDQG6WXG\GUXJ$/13&6 6&LQIRUPDWLRQLVGHVFULEHGEHORZ
7DEOH ,QYHVWLJDWLRQDO3URGXFW
3URGXFW1DPH $/13&6 6&
'RVDJH)RUP 6ROXWLRQIRU,QMHFWLRQ
8QLW'RVH PJYLDOPJP/
5RXWHRI$GPLQLVWUDWLRQ 6&XVH
3K\VLFDO'HVFULSWLRQ &OHDUFRORUOHVVWRS DOH\HOORZVROXWLRQ
HVVHQWLDOO\IUHHRISDUWLFXODWHV 
6WXG\GUXJSUHSDUDWLRQ 7KHSKDUPDFLVWRUGHVLJQHHZLOOSUHSDUHWKHVWXG\GUXJXQGHUDV HSWLF
FRQGLWLRQV2QVWXG\GUXJGRVLQJGD\VWKHSKDUPDFLVWRUGHVLJQ HHZLOOZLWKGUDZWKHUHTXLUHG
DPRXQWRIVWXG\GUXJLQWRRQHV\ULQJHWREHDGPLQLVWHUHGWRWKH VXEMHFWRQWKDWGD\7KH
SURFHGXUHIRUSUHSDULQJVWXG\GUXJDQGWKHYROXPHWREHORDGHG LQWRWKHV\ULQJHLVSURYLGHGLQ
WKH3KDUPDF\0DQXDO
6WXG\GUXJDGPLQLVWUDWLRQ 6XEMHFWVZLOOEHDGPLQLVWHUHG$/13&6 6&PJE\6&LQMHFWLRQ
6WXG\GUXJLQMHFWLRQZLOOEHDGPL QLVWHUHGE\TXDOLILHGFOLQLFDO VWXG\VLWHVWDIIXQGHUWKH
VXSHUYLVLRQRIWKHLQYHVWLJDWRURUGHVLJQHHDQGWKHLQMHFWLRQV LWHZLOOEHPDUNHGDQGPDSSHGIRU
ODWHUREVHUYDWLRQ7KHVLWHRILQMHFWLRQLVWKHDEGRPHQ,IPRU HWKDQRQHLQMHFWLRQLVQHFHVVDU\
WKHILUVWRQ'D\VKRXOGEHRQRQHVLGHRIWKHDEGRPHQDQGWKH VHFRQGRQ'D\RURQWKH
RSSRVLWHVLGHRIWKHDEGRPHQ'RQRWL QMHFWLQWRDUHDVRIDFWLY HVNLQGLVHDVHRULQMXU\VXFKDV
VXQEXUQVVNLQUDVKHVLQIODPPDWLRQRUVNLQLQIHFWLRQV
,IDORFDOUHDFWLRQDURXQG WKHLQMHFWLRQVLWHRFFXUVSKRWRJUDS KVRIWKHLQMHFWLRQVLWHVKRXOGEH
REWDLQHGDWILUVWSUHVHQWDWLRQDQGDWHDFKRIWKHIROORZXSYLV LWVXQWLOWKHLQMHFWLRQVLWHUHDFWLRQ
UHVROYHV,QMHFWLRQVLWHUHDFW LRQVPXVWEHUHSRUWHGDVGHVFULEH GLQ6HFWLRQ 'HWDLOHG
LQVWUXFWLRQVIRUVWXG\GUXJDGPL QLVWUDWLRQDUHIRXQGLQWKH3KD UPDF\0DQXDO
3DFNDJLQJDQG/DEHOLQJ
6WXG\GUXJZLOOEHSURYLGHGE \&DWDOHQW3KDUPD6ROXWLRQV0HGLF DWLRQODEHOVZLOOFRPSO\ZLWK
UHJXODWRU\UHTXLUHPHQWV7KHVWRUDJHFRQGLWLRQVIRUWKHVWXG\G UXJZLOOEHGHVFULEHGRQWKH
PHGLFDWLRQODEHO
$/13&6 6& &OLQLFDO6WXG\3URWRFRO0'&23&6
3URWRFRO$PHQGPHQW 7KH0HGLFLQHV&RPSDQ\
&RQILGHQWLDO 7KH$/13&6 6&6ROXWLRQIRU,QMHFWLRQVXEFXWDQHRXVXVHLVSDFNDJHGLQP/ JODVVYLDOVZLWK
DILOOYROXPHRIQROHVVWKDQP/7K HFRQWDLQHUFORVXUHV\ VWHPFRQVLVWVRID7\SH,JODVV
YLDOD7HIORQIDFHGPPVWRSSHUD QGDIOLSRIIDOXPLQXPVHD O
6WRUDJH
$/13&6 6&ZLOOEHVWRUHGLQDVHFXUHUHIULJHU DWRURUDWWKHDSSURSULDWH FRQGLWLRQVDVVSHFLILHGLQ
WKH3KDUPDF\0DQXDO$FFHVVVKRXOGEHVWULFWO\OLPLWHGWRWKHL QYHVWLJDWRUSKDUPDFLVWVDQG
WKHLUGHVLJQHHV1RVSHFLDOSURFHGXU HVIRUWKHVDIHKDQGOLQJRI $/13&6 6&DUHUHTXLUHG
$FFRXQWDELOLW\
7KHLQYHVWLJDWRURUGHVLJQHH PXVWPDLQWDLQDQLQYHQWRU\UHFRUG RIVWXG\GUXJUHFHLYHGDQG
DGPLQLVWHUHGWRDVVXUHWKHUHJXODWRU\DXWKRULWLHVDQGWKH6SRQV RUWKDWWKHVWXG\GUXJZLOOQRWEH
GLVSHQVHGWRDQ\SHUVRQZKRLVQ RWDVXEMHFWXQGHUWKHWHUPVDQ GFRQGLWLRQVVHWIRUWKLQWKLV
SURWRFRO6WXG\GUXJDFFRXQWDELOLW\IRUPVDQGRUVSHFLILFLQVWU XFWLRQVFDQEHIRXQGLQWKH
3KDUPDF\0DQXDO
7KHVWXG\GUXJVXSSOLHGIRUXVHLQWKLVVWXG\LVWREHSUHVFULE HGRQO\E\WKHSULQFLSDOLQYHVWLJDWRU
RUGHVLJQDWHGVXELQYHVWLJDWRUVDQGPD\QRWEHXVHGIRUDQ\SXU SRVHRWKHUWKDQWKDWRXWOLQHGLQ
WKLVSURWRFRO
'XULQJWKHVWXG\DOOXVHGVWXG\GUX JFRQWDLQHUVHJHPSW\YLD OVERWWOHVZLOOEHNHSWXQWLOWKH
PRQLWRUKDVUHYLHZHGWKHDFFRXQW DELOLW\UHFRUGV
$OOXQXVHGVWXG\GUXJZLOOEH GHVWUR\HGRQVLWHRUUHWXUQHGWR WKHSDFNDJLQJDQGODEHOLQJIDFLOLW\
IRUGHVWUXFWLRQLIGHVWUXFWLRQRQVLWHLVQRWSRVVLEOHRQFHWK HVWXG\GUXJKDVEHHQLQYHQWRULHGDQG
WKHPRQLWRUKDVUHYLHZHGWKHDFFRXQWDELOLW\UHFRUGV,QWKHHYH QWWKDWWKHVWXG\GUXJQHHGVWREH
UHWXUQHGIRUDQ\RWKHUUHDVRQWKH VLWHZLOOUHFHLYHDZULWWHQ UHTXHVWOLVWLQJ WKHGUXJORWQXPEHUV
WREHUHWXUQHGDQGWKHUHDVRQIRU WKHUHWXUQUHTXHVW
3URGXFW&RPSODLQWV
6LWHVDUHUHTXLUHGWRUHSRUWDQ\SURGXFWFRPSODLQWVWR0'&2LPP HGLDWHO\EXWQRODWHUWKDQ
KRXUVIURPWKHWLPHRIDZDUHQHVVE\SKRQHRUHPDLODVIROORZV 
3URGXFW&RPSODLQW ,VGHILQHGDVDQ\ZULW WHQHOHFWURQLFRURUDOFRPPXQLFDWLRQ WKDWDOOHJHV
GHILFLHQFLHVUHODWHGWRWKHLGHQWLW\GXU DELOLW\UHOLDELOLW\ TXDOLW\VDIHW\HIIHFWLYHQHVVRU
SHUIRUPDQFHRIDSURGXFWDI WHULWLVUHOHDVHGIRUGLVWULEXWLRQ (8',5(&'HULYHG
IURP5HI86&)5
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 31 There 
are two types of Product Complaints: 
Technical Quality Complaints : A report of dissatisfaction with product with regard to its 
efficacy, strength, integrity, purity, or quality; thus a potential failure to meet product 
specifications. Examples include: 
ÔÇ∑An indication that there is an unexpected physical change in the drug product such as
discoloration, change in shape of the drug product, presence of particulates or any
other physical change that might indicate contamination, a manufacturing defect or
any other event that might indicate a compromise in product quality.
ÔÇ∑An indication that the content does not meet its labeled volume, count, etc.
ÔÇ∑An indication that there is an unexpected physical change in any part of the container
(this includes the bottle, any part of the seal, the cap or the label).
ÔÇ∑An indication that the product is mislabeled.
ÔÇ∑An indication that there is an unexpected physical change of the product or container
once the product is diluted or reconstituted (the container includes the vial, bag, IV
line, syringe or any other item that is in contact with the product).
ÔÇ∑An indication that the product is falsified, tampered with or adulterated.
ÔÇ∑An indication that the pr
oduct did not meet its pharmacologic effect, i.e. lack of
efficacy.
ÔÇ∑Medical Device Incidents
Preference Complaints : A report of dissatisfaction with service, delivery, packaging or other 
preference. 
5.2. Concomitant Medications 
5.2.1. Required Concomitant Medication(s) and Diet 
Subjec
ts who meet inclusion/exclusion criteria will be instructed to continue to follow a NCEP 
Adult Treatment Panel III (or comparable) diet and be required to maintain their current lipid 
lowering drug therapy for the duration of the study. 
5.2.2. Prohibited Concomitant Medications  
The following medications/treatments are not permitted to be added during the study: 
ÔÇ∑Medications used to lower LDL-C (eg, statins, ezetimibe, lomitapide, mipomersen,
niacin, colesevelam, bile acid absorption inhibitors, monoclonal antibodies directed
towards PCSK9).
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 32 5.2.3. Permitted Concomitant Medication(s)  
The following
 medications/treatments are permitted during the study: 
ÔÇ∑Hormone replacement therapy
ÔÇ∑Lipid-lower medications; subjects on lipid-lower medications (such as statins and/or
ezetimi
be) should be on a stable dose for ‚â•30 days before screening with no planned
medicati
on or dose change during study participation
ÔÇ∑Prescription medications prescribed to treat pre-existing medical conditions such as
diabetes and hype
rtension
ÔÇ∑Prescription or nonprescription medications, when necessary to treat an AE, at the
discretion of the inve
stigator
5.3. Medical Management Guidelines 
If a local reaction around the injection site occurs, photographs of the injection site should be 
obtained at first pre
sentation and at each of the follow-up visits until the injection site reaction 
resolves. Injection site reactions must be reported as described in  Section 8.2.3 . Detailed 
inst
ructions for study drug administration are found in the Pharmacy Manual.  
5.4. Res
trictions  
Subjects will have to comply with the following restrictions during the study: 
ÔÇ∑Fasted for at least 8 hours for all visits for fasting lipids and glucose blood samples
ÔÇ∑Blood donation will not be allowed at any time during the study
ÔÇ∑Must refrain from unaccustomed strenuous physical exercise for 48 hours before the
screening
 and any study visit until the follow-up has been completed
5.5. Blinding  
Not applicable, this is not a blinded study. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 33 6. SCHEDU
LE AND SEQUENCE OF PROCEDURES 
The Schedule of Events/Assessments (Section 6.1) summarizes the study assessments by time 
point.  
This s
tudy consists of four periods:  Screening, Treatment, End of Study and Additional Follow-
up.   
ÔÇ∑The Sc
reening period occurs prior to administration of study drug and consists of
confirmi
ng eligibility.
ÔÇ∑The Treatment period occurs from the time of enrolling the subject, collecting Day 1
assessments and study
 drug administration through Day 90/104.
ÔÇ∑The End of S
tudy visit occurs at Day 180.
ÔÇ∑The Additional Follow-up period (if necessary) occurs from end of study through Day
300. 
ÔÇ∑The maxim
um duration of a subject‚Äôs participation is from screening/informed
consent to end of
 study (last follow-up) and is expected to be up to 328 days.
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
 Protocol Amendment 1 The Medicines Company 
Confidential 34 6.1. Schedule of Events/Assessments 
Screening Treatment Phase  End of 
Study (EOS)  Additional Follow -Up p 
Study Day  -28 to -1 Day 
1 FU1 
Day 14 
(¬± 2d) FU2 
Day 30 
(¬± 3d) FU3 
Day 60 
(¬± 3d) FU4 
Day 90 
(¬± 3d)  
Dose 2? a FU4X 
Day 104 
(¬± 3d) 
Dose 2? a FU5 
Day 120 
(¬± 3d) FU6 
Day 150 
(¬± 3d) FU7 
Day 180 
(¬± 3d) FU8 (Day 210) (¬± 3) 
FU9 (Day 240) (¬± 3) 
FU10 (Day 270) (¬± 3) 
FU11 (Day 300) (¬± 3) 
Informed consent X 
Medical History and prior 
meds X 
Physical Examination & 
full neurolog ic exam X X 
Inclusion / Exclusion 
Criteria X X 
Pharmacogenetic sample o X 
Enrollment  X 
Vital Signs b X X X X X X X X X X 
12 Lead ECG c X X 
Hematology, 
Coagulation d,  f X X X X X X X X X X X 
Biochemistry, 
Inflammatory markers d, f X X X X X X X X X X X 
HbA1c X X X X X n 
Urinalysis e, X X g X X 
Pregnancy test e, h X X h X X X X h X h X X X X i 
ADA antibodies  j X j, k X X k X k  X k 
Lipids / lipoproteins  m X X X X X X X X X X X 
Biomarker (stored  
samples)q X X X X X X X X X X X 
Study drug admin  X X a X a 
Concomitant medications  X X X X X X X X X X X 
AE reporting  X X X X X X X X X X 
SAE reporting  X X X X X X X X X X 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
Protocol Amendment 1 The Medicines Company 
Confidential 35 ADA = anti -drug antibodies; AE = adverse event; ECG = electrocardiogram; FU=follow -up; EOS = end of study; hsCRP=high sensitivity C -reactive protein ; 
IL6=interleukin 6; IFN -Œ≥=interferon gamma; LDL -C = low -density lipoprotein cholesterol; PCSK9 = proprotein  convertase subtilisin/kexin type 9; SAE = 
serious adverse event; TNF -Œ±=tumor necrosis factor alpha.  
a Day 104 visit only for those subjects who receive a second dose of study drug . Dose # 2 may be given at Day 90 or 104 depending on PCSK9 levels as compared 
to baseline 
b Vital signs: blood pressure and heart rate will be measured prior to injection and at 4 hours after injection. 
c ECG is performed prior to the injection on Day 1. 
d Hematology, chemistry (including lactate, bicarbonate, glucose, HbA1c, liver and renal function, hsCRP, IL6, IFN-Œ≥, and TNF-Œ±), and coagulation testing. 
Blood samples for determination of laboratory values will be performed prior to study drug injection where relevant. All laboratory testing will be performed 
with subjects in a fasted state.  
e Lab tests performed in participating institution‚Äôs laboratory. Results must be available before the start of study drug injection on Day 1 to confirm subjects meet 
eligibility criteria. 
f Lab tests performed by study‚Äôs designated Central Lab facility from enrollment to EOS. In addition, subjects in whom LDL- C reduction is less than 20% of the 
absolute reduction from baseline to Day 90 will continue to be followed up on a monthly visit schedule either until this level has been reached or until Day 
300.  
g Urinalysis collection is prior to the injection on Day 1.
h Urine pregnancy test performed at each visit for females of childbearing potential. In addition, postmenopausal women who are less than  55 years of age will 
have a pregnancy test within 24 hours of enrollment and prior to any study drug injection .  Results must be available prior to the injection on Day 1 and, if a 
second dose of study drug is required, on Day 90/104. 
i Females of childbearing potential will have a pregnancy test at each additional follow-up visit until LDL- C reduction is less than 20% of the absolute reduction 
from baseline to Day 90. 
j Two ADA samples will be drawn on Day 1: one before the injection and one 4 hours after the injection. 
k Additional aliquots of plasma and serum will be collected at each time point and stored for future analyses. 
l For subjects in whom LDL- C reduction is less than 20% of the absolute reduction from baseline to Day 90, formation of ADA will be assessed at the last visit. 
m Efficacy parameters (Lipids / lipoproteins) will include LDL-C, total cholesterol, triglycerides, HDL-C, non-HDL-C, very low-density lipoprotein (VLDL-C), 
apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), lipoprotein(a) [Lp(a)], and PCSK9. 
n Day 270 only. 
oSample may be taken during screening or anytime during study to be processed and stored, but only after separate consent has been signed.
p Additional Follow- Up visits only for those subjects in whom LDL- C reduction is less than 20% of the absolute reduction from baseline to Day 90. 
q 3 aliquots of plasma and 3 aliquots of serum will be stored for efficacy and safety biomarker analysis if needed. All samples will be destroyed 1 year following 
the last subject's last visit in the study. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 36 6.2. Genera
l Conduct of the Trial 
Written informed consent will be obtained for this study by the principal investigator or sub-
investigator from all subjects before the performance of any protocol-specific procedure (if the 
subject is less than 18 years of age, written consent will be obtained from their guardian or 
legally authorized representative, with verbal assent from the child).  
Please
 see Section 6.1 for detailed schedule, and Sec tion 7 for listings of all tests required in each 
panel. 
 
6.3. Screening Period (Days ‚Äì 28 to ‚Äì1 ) 
The following procedures will be performed within 28 days prior to enrollment: 
All scre
ening laboratory tests will be analyzed at the Central L ab, with the exception of 
urinalysis and pregnancy test, which will be done in-house at the participating institution‚Äôs 
laboratory using the testing materials provided by the Central Lab.  The results of all screening 
laborator
y tests should be reviewed prior to enrollment.  If these results confirm an exclusion 
criterion or suggest any contraindication to treatment with ALN-PCS SC, and/or other required 
ancillary medication(s), the subject must not be enrolled. 
1. Review of inclusion/exclusion criteria to confirm subject eligibility.
2. Documentation of
:
a.Demography: 
age, gender and ethnic origin
b. Medical history
c.Concomitant medica
tions
3. Full physical examination including height, weight and full neurological examination (as
describe
d in Appendix A ).
4. Vital si
gns (blood pressure and heart rate).
5. Blood s
amples drawn for screening clinical laboratory tests and results reviewed prior to
enrollme
nt.  All laboratory testing will be performed with subjects in a fasted state.
a.Biochemistry
b. Inflammatory markers
c.Lipids/lipoproteins
d.
Hematology
e.Coagulation
f.HbA1c
g.B
iomarker (stored samples)
h. Pharmacogenetics (stored samples, only if separate consent has been signed)
6. Urinalysis
 (local), using standardized supplies from Central Lab.
7.Urine pre
gna ncy test (local), using standardized supplies from Central Lab, for females of
childbe
aring potential. In addition, postmenopausal women who are less than 55 years of
age must
 have a negative pregnancy test within 24 hours of enrollment.
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 37 6.4. Enrol
lment (Day 1) 
Enrollment should only occur once subject eligibility is confirmed.  
The following procedures will be performed prior to the injection of study drug : 
1. Review of inclusion/exclusion criteria
2. Vital signs (blood pressure and heart rate will be measured prior to injection and at 4
hours after inje
ction)
3. 12-lead ECG
4. Blood s
amples drawn for clinical laboratory tests (Central Lab):
a.Biochemi
stry
b. Inflammatory markers
c.Lipids/lipoproteins
d. Hematology
e.Coagulation
f.HbA1c
g.Anti-ALN-PCS SC (ADA) antibodies (prior to and 4 hours after the injection)
h. Biom
arkers (stored samples)
5. Urinalysis (local)
6. Urine pregnancy test (local), for females of childbearing potential. In addition,
postmenopausal women less than 55 years of age will have a pregnancy test within 24
hours of enrollm
ent.  Results must be available prior to the first injection of study drug
7. Conc
omitant medications
8. AE reporting
9. SAE reporting
10. Enrollment (only after subject eligibility is confirmed)
If eligible, the subject will receive the first injection (SC) of study drug and will be observed in 
the clinic f
or at least 4 hours post- injection be fore being discharged. The site of injection is the 
abdomen. T
he injection site will be marked and mapped for later observation 
The following procedures will be performed 4 hours after the injection: 
11. Vital signs: blood pressure and heart rate
12. Blood s
amples drawn for Anti-ALN-PCS SC (ADA ) antibodies
13. Concomitant medications
14. AE reporting
15. SAE reporting
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 38 6.5. Fo
llow-up Visits FU 1-6 
Subjects will return to the study center after study drug administration for Follow-Up Visit s 
according to the Schedule of Events/Assessments ( Section 6.1) until the end of the study.  
Proc
edures will be as follows: 
1. Vital signs (blood pressure and heart rate will be measured prior to injection and at 4
hours after inje
ction)
2. Blood samples drawn for clinical laboratory tests:
a.Biochemistry
b.
Inflammatory markers
c.Lipids/lipoproteins
d.
Hematology
e.Coagulation
f.HbA1c
 (only at Days 90 and 180 and Day 270 if applicable)
g.Anti-A
LN-PCS SC (ADA) antibodies (only at Day 30 and Day 150)
h. Biom
arkers (stored samples)
3. Urine preg
nancy test (local) for females of childbearing potential.  In addition, on Day 90
or 104 (if a
 second dose of study drug is required), postmenopausal women less than 55
yea
rs of age will have a pregnancy test and results must be available prior to the injection
4. Conc
omitant medications
5. AE reporting
6.
SAE reportin
g
7. Study d
rug administration ONLY  for subjects requiring a second dose of study drug
(depe
nding on the degree of suppression of serum PCSK9 as compared to baseline).
If a second dose is deemed necessary, the subject will receive the injection (SC) at Day
90 or 104, ba
sed on the PCSK9 levels from the previous visit. The site of injection is the
abdomen (on the opposit
e side than the injection on Day 1).  The injection site will be
marked and mapped for later observation
6.6. End of Study (EOS) Visit (FU 7) 
A subject‚Äôs participation in the study is complete when all procedures at the last study visit have 
been c
ompleted and all ongoing SAEs have been followed to resolution (refer to Section 8.1.1 ). 
Procedures will be as follows: 
1. Vital signs (blood pressure and heart rate)
2. Ph
ysical examination (including full neurological examination as described in
Appendix A )
3. 12-lea
d ECG
4. Blood s
amples drawn for clinical laboratory tests:
a.Biochemistry
b.
Inflammatory markers
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 39 c.Lipids/l
ipoproteins
d. Hematology
e.Coagulation
f.Anti-ALN-PCS SC (ADA) antibodies
g.Bioma
rkers (stored samples)
5. Urinal
ysis (local)
6. Urine pregnancy test (local) for females  of childbearing potential
7. C
oncomitant medications
8. AE reporting
9. SAE reporting
6.7. Additional Follow-Up  Visits (FU 8-11, if needed) 
These visits are only for those subjects in whom LDL- C reduction is less than 20% of the 
absolute reduction from baseline to Day 90. Procedures will be as follows: 
1. Blood samples drawn for clinical laboratory tests:
a.Biochemistry
b. Inflammatory markers
c.Lipids/lipoproteins
d. Hematology
e.Coagulation
f.HbA1c (only at Day 270)
g.Anti-A
LN-PCS SC (ADA) antibodies (only at last visit)
h. Biom
arkers (stored samples)
2. Urinalysis (local)
3. Urine pregnancy test (local). Females of childbearing potential will have a pregnancy test
at eac
h additional follow-up visit unti l LDL- C reduction is less than 20% of the absolute
reduction from baseline to Day 90
4. Concomitant medications
5. AE reporting
6. SAE reporting
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 40 7. PROTOC
OL ASSESSMENTS 
7.1. Assessment of Safety 
7.1.1. Adverse Events 
Subjec
ts will be carefully monitored for adverse events by the investigator during the designated 
study period (see Section 6.1 for details).   
7.1.2. Demographics and Medical History 
Ba
seline demographic information will be collected during screening, and will include age, sex 
and race/ethnicity. 
Relevant medical history includes all ongoing medical or surgical issues. Remote medical and 
surgical history > 5 years from the time of screening should only be included if considered 
relevant to the study. 
7.1.3. Vital Signs  
Vital signs will include heart rate and blood pressure. 
7.1.4. Electrocardiograms 
12-L
ead ECGs will be collected at Day 1 and at the EOS visit only, unless clinically indicated. 
7.1.5. Physical Examination 
The physical examination should include a focused examination, which may include general, 
respirator
y, cardiovascular, abdominal, extremities, and recording of height, weight. 
The phy
sical examination should also include a full neurologic evaluation as described in 
Appendix A .
 
7.1.6. Clinical Laboratory Assessments 
Spe
cimens will be obtained at the time points in the Schedule of Assessments ( Section 6.1). Additional 
aliquots
 of plasma or serum will be collected at each time point and stored for any clinically indicated 
efficacy or safety analyses to be conducted at the end of the study.  
Subjects will be in a fasted state for all clinical laboratory assessments. Screening lab tests will be 
performe
d by the Central L ab, with the exception of urinalysis and pregnancy test, which will be done 
in-house at the participating institution‚Äôs laboratory using testing materials supplied by the Central 
Lab. Results from these screening tests must be available before the start of study drug injection on 
Day 1 to conf
irm subjects meet eligibility criteria. Details regarding the processing, shipping, and 
analysis of samples will be provided in the Laboratory Manual. Note: Efficacy laboratory assessments 
(e.g., LDL-C and PCSK9) are described in Section 7.2 . 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 41 Labo
ratory assessments will include: 
Biochemist
ry: AST, ALT, alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), 
uric ac
id, total bilirubin (TBIL), direct bilirubin, indirect bilirubin, lactate, bicarbonate, sodium, 
crea
tine kinase (CK), albumin, total protein urea (BUN), creatinine, potassium, chloride, glucose 
(fasti
ng), inorganic phosphate, eGFR, calcium, and tryptase (as required). 
Inflam
matory markers:  hsCRP (fasting), IL6, IFN-Œ≥, and TNF-Œ± 
Hematology:  he
moglobin, hematocrit, erythrocytes, reticulocytes, platelet counts, mean cell 
hemoglobi
n (MCH), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration 
(MCHC), white blood cell count, differential blood count. 
Coagulation: prothr
ombin time (PT), international normalized ratio (INR), activated partial 
thromboplastin (aPTT). 
HbA1c:  hemoglobin A1c 
Urinalysi
s: Urinalysis will be performed at the time points defined in the Schedule of Assessments 
and evaluated by
 dipstick analyses at the investigational site local lab (a standardized dipstick test will 
be supplied by the Central Lab). Urinalysis will be performed from a sample of mid-stream urine. In 
case of abnormal results, microscopy and other assessments will be performed at the local lab. The 
following parameters will be assessed: Nitrite, protein, glucose, ketone, urobilinogen, bilirubin, red 
blood cells (R BC)/erythrocytes, white blood count (WBC)/leukocytes, pH, urine sediment 
(microscopic e
xamination will be performed in the event of abnormalities). 
Urine pregnancy: Urine pregnancy testing will be conducted locally at the visits specified in the 
Schedule of Assessments (a standardized pregnancy test will be supplied by the Central lab). 
7.1.7. Anti-ALN-PCS SC Antibodies 
Additional sample for analysis of the induction of antibodies will be collected at the time points 
in the Schedule of Assessments ( Section 6.1).  
Aliquots of serum sa
mples will be obtained and frozen, to permit future analysis of the effect of ALN-
PCS SC on the expression of these exploratory biomarkers. Biological samples for biomarker research 
will be re
tained on behalf of the Sponsor for one year following the last subject's last visit in the study. 
Details regarding the collection, processing, storage, and shipping will be in the Study Laboratory 
Manual.  
7.2. Assessment of Efficacy 
Specimens for assays of lipids/lipoproteins will be obtained at the time points in the Schedule of 
Assessme
nts (Section 6.1 ). Subjects will be in a fasted state for all efficacy laboratory 
a
ssessments. Parameters to be assessed will include: total cholesterol (TC), triglycerides, LDL-C, 
HDL-C, non-HDL-C, very low-density lipoprotein (VLDL-C), apolipoprotein A1 (Apo- A1), 
apoli
poprotein B (Apo-B), lipoprotein(a) [Lp(a)], and PCSK9. 
7.2.1. Change in LDL-C 
The prima
ry efficacy endpoint is the percentage change in LDL-C. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 42 In a
ddition, this study will assess absolute  and percentage  cha nge in LDL- C as a secondary efficacy 
endpoint. 
Blood sa
mples for determination of LDL-C (Œ≤-quantification) concentrations will be collected at the 
time points in the Sche
dule of Assessments. Details regarding the collection, processing, shipping, and 
storage of the samples will be provided in a Laboratory Manual.  
7.2.2. Change in Lipids/Lipoproteins 
Se
condary efficacy assessments will include measurement of the effects of ALN-PCS SC on levels of 
lipids and lipopro
teins including total cholesterol, triglycerides, LDL-C, HDL-C, non-HDL-C, VLDL-
C, Apo-A1, Apo-B, Lp(a), and PCSK9.  
ÔÇ∑Absolute
 change and percentage change in PCSK9 levels
ÔÇ∑Absolute
 change and percentage change in other lipids, and apolipoproteins
ÔÇ∑Biomar
kers (stored samples): Additional aliquots of plasma and serum will be collected
at eac
h time point and stored for additional analyses, including future analysis of
biomarke
rs of CV risk. These samples will be retained for 1 year following the last
subjec
t's last visit in the study.
Plasma samples will be analyzed using a validated enzyme linked immunosorbent assay to determine 
PCSK9 protein concentration. Full details of the analytical methods used will be described in a 
separate bioanalytical report.  
7.3. Assessment of Pharmacogenetics 
A blood sample will be collected, preferably during screening,  only from subjects who sign a 
separate consent for pharmacogenetics. Samples will be processed as described in the Laboratory 
Manual and store
d. Genetic assessment will be performed by an accredited laboratory. This 
assessment will determine if there is a different response for LDL-C lowering based on the type 
of mutation(s). 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 43 8. ADV
ERSE EVENTS 
8.1. Definitions 
8.1.1. Adverse Event 
Adverse
 Event (AE): Any untoward medical occurrence in a patient or clinical trial subject 
administered a medicinal product and which does not necessarily have a causal relationship with 
this treatment. An adverse event can therefore be any unfavorable and unintended sign (eg, an 
abnormal l
aboratory finding), symptom, or disease temporally associated with the use of a 
medicinal product, whether or not considered related to the medicinal product.  
Planned hospital admissions and/or surgical operations for an illness or disease that existed 
before the study drug was given or the subject was randomized in a clinical study are not to be 
considered AEs. 
Adverse 
events or abnormal test findings will be followed until the event (or its sequelae) or the 
abnormal test finding resolves or stabilizes at a level acceptable to the Sponsor/Investigator. 
8.1.2. Serious Adverse Event 
A serious adverse event (SAE) is any untoward medical occurrence that at any dose: 
ÔÇ∑Results in death,
ÔÇ∑Is life-threatening, i.e., the subject was, in the opinion of the investigator, at
immediate risk of death from the event as it occurred (it does not include an event
that, had it occurred in a more severe form, might have caused death),
ÔÇ∑Result
s in a significant, persistent or permanent change, impairment, damage or
disruption in the subject's body function/structure, physical activities and/or quality of
life,
ÔÇ∑Requires in-subject hospitalization or prolongs hospitalization,
ÔÇ∑Is a congenital anomaly/birth defect, or
ÔÇ∑Is another medically significant event where medical and scientific judgement should
be exercised in deciding whether other situations should be considered serious
reactions, such as important medical events that might not be immediately life
threatening or result in death or hospitalization but might jeopardize the subject or
might require intervention to prevent one of the other outcomes listed above.
Examples of such events are intensive treatment in an emergency room or at home for
allergic bronchospasm, blood dyscrasias or convulsions that do not result in
hospitalization or development of dependency or abuse. Any suspected transmission
via a medicinal product of an infectious agent is also considered a serious adverse
reaction.
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 44 8.1.3. Medication Errors 
Medica
tion error refers to any unintended error in the dosing and/or administration of the study 
drug as per instructions in the protocol.  Medication errors generally fall into 4 categories as 
follows: 
ÔÇ∑wrong study drug;
ÔÇ∑wrong dose (including dosing regimen, strength, form, concentration, amount,
including above the maximum or under the minimum recommended dose );
ÔÇ∑wrong route of administration;
ÔÇ∑wrong subject (i.e. not administered to the intended subject)
8.2. EVA
LUATING ADVERSE EVENTS 
8.2.1. AE Severity  
The severity of an AE will be assessed by the investigator.  The investigator should ensure that 
any subject experiencing an AE receives appropriate medical support until the event resolves. 
Adverse events (AE) will be graded on a 3-point scale and reported as indicated on the case 
report form.  The intensity of an AE is defined as follows: 
1 = Mild: Discomfort noticed, but no disruption to daily activity. 
2 = Moderate: Discomfort sufficient to reduce or affect normal daily activity. 
3 = Severe: Inability to work or perform normal daily activity. 
A distinction should be drawn between serious and severe AEs. Severity is an estimate or 
measure of the intensity of an AE, while the criteria for serious AEs are indications of adverse 
subject outcomes for regulatory reporting purposes. A severe AE need not necessarily be 
considered serious and a serious AE need not be considered severe. For example, nausea that 
persists for several hours may be considered severe nausea, but not an SAE. On the other hand, a 
myocardial infarction (MI) that may be considered minor could also be an SAE if it prolonged 
hospitalization. 
8.2.2. Study Drug Causality  
The relationship of an AE to study treatment (i.e. ALN-PCS SC) will be assessed with 
consideration to the following criteria: 
ÔÇ∑Temporal relationship to the initiation of study medication
ÔÇ∑Response of the event to withdrawal of study medication
ÔÇ∑AE profile of concomitant therapies
ÔÇ∑Clinical circumstances during which the AE occurred
ÔÇ∑Subject‚Äôs clinical condition and medical history
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
Protocol Amendment 1 The Medicines Company 
Confidential 45 Categoriza
tion of causality will be designated by the investigator as stated below: 
Reasonable possibility  - There are facts (evidence) or arguments to suggest a causal relationship 
between the event and t he study drug.   
No Reasonable possibility  - There are few to no facts (evidence) or arguments to suggest a 
causal relationship between the event and the study drug. 
8.2.3. Adverse Event of Special Interest (AESIs) 
An adverse event of special interest (serious or nonserious) is one of scientific and medical 
concern specific to the Sponsor‚Äôs study drug or program, which warrants ongoing monitoring 
and rapid communication by the investigator to the sponsor. Such an event might warrant further 
investigation in order to characterize and understand it. 
The following AESI(s) have been identified for the study drug ALN-PCS SC in this protocol. 
ÔÇ∑Injec
tion site reactions (ISR)
Injec
tion site reactions including individual signs or symptoms at the injection site reported 
following study drug administration will be collected as an AESI. 
The grade (severity) of injection site reaction will be determined by the Common Terminology 
Criteria for Adverse Events (CTCAE) criteria of Injection Site Reaction (General disorders and 
administration site conditions) (see Table 2).  
Table 2:
 Common Terminology Criteria for Adverse Events (CTCAE ) of Inject ion 
Site Reaction  
Grade I: Tenderness with or without associated symptoms (eg , warmth, erythema, itching)  
Grade II: Pain; lipodystrophy; edema; phlebitis  
Grade III Ulceration or necrosis; severe tissue damage; operative intervention indicated  
Grade IV Life -threatening consequences; urgent intervention indicated  
Grade V Death  
Reference: Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 3, Published 14 June 2010 . 
As indicated in Section 5.3 and Section 8.2.3 , photographs of ISR should be obtained either by 
the investigator or another health care professional at first presentation and at each of the follow-
up visits until the injection site reaction resolves, if possible.  
Potential ana
phylactic reactions will be assessed using the Sampson Criteria ( Appendix B ). 
8.2.4. Special Situations 
Coll
ection, evaluation, and/or reporting of safety information is required by the regulatory 
authorities in special situations.  
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 46 The spec
ial situations not previously defined include the following: 
ÔÇ∑Suspected transmission via a medicinal product of an infectious agent
ÔÇ∑Drug interactions
ÔÇ∑Occupational exposure
8.3. PROCED
URE FOR ADVERSE EVENT REPORTING 
8.3.1. Procedure for Non-Serious Adverse Event Recording 
All non-serious AEs that occur during the designated study period from enrollment up to EOS 
must be assessed and recorded on the source documents and eCRF, regardless of causal 
relationship t
o the study drug.   
8.3.2. Procedure for Serious Adverse Event Reporting 
All SAEs that oc
cur during the designated study period from enrollment up to EOS must be 
reported to t
he Sponsor‚Äôs Global Pharmacovigilance Department (GPV) within 24 hours of 
awareness of the event using the provided study specific SAE/AESI Report Form.  In addition to 
completing the SAE/AESI Report Form, each SAE/AESI must be entered on the appropriate 
page of the case report form (CRF ).   
The investigator must assess the causality for each SAE/AESI. 
The Sponsor will contact the investigator, if necessary, to clarify any of the event information. 
The investigator should provide any follow-up information for the event to the Sponsor on an 
updated SAE/AESI report form as soon as it becomes available. 
If the investigator is notified of a SAE/AESI that occurs post-study period, that he or she wishes 
to report to the Sponsor (e.g., an event suspected to be causally related to study drug), the event 
should be reported through the process described above.  
Where appropriate, if required by local regulations or procedures, the investigator should report 
these events to the Institutional Review Board (IRB)/Ethics Committee (EC) and/or national 
regulatory authority in addition to the Sponsor. 
8.3.3. Procedure for Medication Error Reporting For Study Drug 
Medicati
on errors with or without an associated AE need to be recorded as medication errors in 
the eCRF as described in Section 8.1.3. 
Medicati
on errors with an associated SAE need to be recorded as medication errors in the eCRF 
and reported to the Sponsor‚Äôs Global Pharmacovigilance Department as described in 
Section 8.3.2. 
8.3.4. Procedure For Reporting Adverse Events Of Special Interest (AESIs) 
Injection Site Reaction has been identified as an AESI for the study product(s) in this protocol as 
per Section 8.2.3. The SAE/AESI form should be utilized for reporting the AESI even if a 
serious outcome ma
y not apply, and the form should indicate that the reported event is an AESI. 
Non-serious AESIs should be reported to the Sponsor within 72 hours and serious AESIs should 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 47 be report
ed to the Sponsor within 24 hours. In both instances, the reporting procedure provided 
in Section 8.3.2 should be followed.  
8.3.5. Procedure For Reporting Pregnancies Exposure 
Occ
urrences of pregnancy in a study subject or study subject‚Äôs partner should be reported within 
24 hours using the Pregnancy Reporting Form. In cases where a pregnancy occurs with a Serious 
Adverse Ev
ent, the Serious Adverse Event reporting form should be used to report the 
SAE/AES
I and the Pregnancy Reporting form should be used to report the pregnancy. When a 
pregnancy occurs without any concurrent SAE, the Pregnancy Reporting Form may be submitted 
alone.  The pregnancy must be followed through to outcome of pregnancy.  Any pregnancy 
discovered from the time of consent to follow-up needs to be reported. 
8.3.6. Procedure For Reporting Special Situations 
The oc
currence of a Special Situation event, defined in Sec tion 8.2.4 , must be report ed to the 
Sponsor as pe
r Section 8.3.2 , Procedure for Serious Adverse Event Reporting. Note: The Special 
S
ituations event does not need to be serious to be reported on the SAE/AESI Report form. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 48 9. DATA
 COLLECTION 
An electronic data capture (EDC) system which is 21 CFR Part 11 compliant will be used for 
this trial.  All users will be trained on the technical features of the EDC as well as the content of 
the eCRF by qualified personnel prior to gaining access to the EDC.  A UserID/Password will be 
granted after training.  This ID is not to be shared amongst the study staff.  All users must have a 
unique account to enter or review data.  The eCRF should be filled out by the site 3 days after 
each visit.  It is not expected that the eCRF will serve as source for any data collected in this 
trial.  If there is a reason for a site to do so, it must be approved by Sponsor and documented in 
the site files. 
Prior to the database being locked, the investigator or designee will review, approve and 
sign/date each completed eCRF.  This signature serves as attestation of the Investigator‚Äôs 
responsibility for ensuring that all data entered into the eCRF are complete, accurate and 
authentic.  After the end of the trial, a copy of the data will be provided to the site.  This copy 
will contain the final data, an audit trail of activity on the data, and any queries and answers that 
were posted for data clarification. 
For this study, the End of Trial will be defined as the last visit of the last subject. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 49 10. STATIST
ICAL PLAN
This is an 8-10 subject non-randomized pilot study. Subjects with homozygous familial 
hype
rcholesterolemia will be recruited from approximately 5 sites globally.  Subjects that qualify 
for entr
y into the study will be enrolled to receive ALN-PCS SC.  The primary  objective of this 
study is to characterize the effect of 90 and 180 days of subcutaneous ALN-PCS SC on the percent 
chan
ge from Day 1 in low-density lipoprotein cholesterol (LDL-C) in subjects with homozygous 
famili
al hypercholesterolemia.  A separate Statistical Analysis Plan (SAP) document will provide 
more detailed specifications in data analysis and presentation. 
The primary hypothesis is that ALN-PCS SC, when used in combination with maximally tolerated 
statin therapy with or without ezetimibe, will be well-tolerated, will suppress circulating PCSK9 
>70% and will result in reduction of LDL-C, defined as mean percent change from Day 1 
following 90 and 180 days of treatment, in subjects with homozygous familial 
hypercholeste
rolemia.  
10.1. Sample Size  
The sample size was chosen based on clinical considerations. 
10.2. Randomization 
This study is non-randomized. 
10.3. General Statistical Considerations and Definitions 
10.3.1. General Statistical Methods 
All study-collected data will be summarized by treatment group using descriptive statistics, 
graphs, and/or raw data listings. Descriptive statistics for continuous variables will include 
number of subjects (n), mean, standard deviation (SD), median, quartiles (Q1 and Q3), minimum 
(min) and maximum (max) values. Analysis of categorical variables will include frequency and 
percentage. 
Summary statistics for continuous variables will include the number of subjects, mean, median, 
standard deviation or standard error, minimum and maximum. For categorical variables, the 
frequency and percentage will be given.  
10.3.2. Analysis Populations 
The following populations will be used for data analyses and/or presentation. 
10.3.2.1. Modified Intent- to-Treat (mITT) Population 
All ITT subjects (who receive at least one dose of study drug ), who have baseline and at least 
one post-baseline measurement for the primary endpoint.  This will be the primary population for 
the efficacy analyses; unless specified otherwise, the mITT will be the default analysis set in this 
study.
 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 50 10.3.2.2. Saf
ety Population 
All subjects who received at least one dose of study drug. Treatment classification will be based 
on the actual treatment received. This will be the primary population for the safety analyses. 
The primar
y analysis set is the modified Intent- to-Treat (mITT), which will include all enrolled 
subjects who have received at least one dose of study drug. Unless specified otherwise, the mITT 
will be the de
fault analysis set in this study. 
10.3.3. Analysis Windows and Baseline 
The observational period for the study includes the screening period (Day -28 to Day -1) , 
treatm
ent and follow up period (Day 1 to Day 180), additional follow up period (up to Day 300, 
only for
 subjects in whom LDL -C reduction is less than 20% of the absolute reduction from 
baseline to Day 90). Any event occurring beyond the defined observational period, even if 
colle
cted on the CRF, will not be included in the planned statistical analysis.  However, all data, 
including that reported after the defined observational period, will be included in the subject data 
listings.   
Unless otherwise specified, for evaluations that are collected at multiple occasions prior to 
initia
tion of study drug administration, the latest evaluation will be considered the "Baseline" 
evaluation for
 analysis. 
10.3.4. Missing Data Handling 
Missing data will not be imputed. 
10.
4. Statistical Analyses 
10.4.1. Demographic and Background Characteristics 
Subject demographics and baseline characteristics will be summarized by treatment group using 
the mITT and safety populations. 
10.4.2. Study Drug and Concomitant Medications 
Summary of each prior (pre-Day 1) medication and concomitant (Day 1 or later) medication will 
be provided b
y treatment.  [Medication will be coded with WHO drug dictionary]. Subjects will 
be counted only once within each period by medication. 
10.4.3. Efficacy Analysis 
10.4.3.1. Primary Efficacy Endpoint 
The primary endpoint is the percent chang e in LDL-C following 90 and 180 days of treatment. 
Summa
ry statistics and 95% CI of this primary endpoint will be provided. Changes of LDL- C 
from Day 1 by scheduled visits will also be summarized. Response rate of subjects with 15% or 
gre
ater reduction in LDL-C from Day 1 following 90 and 180 days of treatment will be 
calcula
ted. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 51 The ana
lysis for the primary endpoint will be descriptive. Means and confidence intervals will be 
provided. 
10.4.3.2. S
econdary Efficacy Endpoints  
Analyses of secondary efficacy endpoints will be similar to the primary analysis of the primary 
endpoint.  
10.4.3.3. Tertiary Efficacy Endpoints  
Formation of Anti-drug antibodies (ADA) to ALN-PCS SC 
Response of LDL-C by the causal genetic mutations of HoFH 
10.4.4. Saf
ety Analysis 
Safety summaries will include the incidence of adverse events, summaries of laboratory 
parameters (including shift tables), vital signs, ECGs and anti-drug antibodies. 
10.4.4.1. Adverse Events 
The Medical Dictionary for Regulatory Activities (MedDRA) will be used for coding adverse 
events (AE
s).  An AE (classified by preferred term) occurring during the study drug treatment 
period will be counted as a treatment emergent AE (TEAE) either if it is not present at baseline 
or if it is present at baseline but increased in severity during the treatment period. 
The number (percentage) of subjects reporting TEAEs for each preferred term will be tabulated 
by system-organ class, by system-organ class and severity, and by system-organ class and 
relationship t
o study drug.  If more than one event occurred with the same preferred term for the 
same subject, the subject will be counted only once for that preferred term using the most severe 
or related occurrence for the summary by severity, or relationship to study drug, respectively. 
10.4.4.2. Laboratory Tests 
Laboratory values will be summarized by treatment group, including changes and percent 
changes from Day 1 at each time point. Analyses will also be performed for each lab parameter 
by treatment group for incidence rates of potentially clinical significant (PCS) values for subjects 
without PCS value at baseline. 
10.4.4.3. Vital Signs  
Change and percent change from baseline in vital signs will be summarized descriptively at each 
scheduled time point by treatment group. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 52 11. RECOR
DS RETENTION
FDA regulations require all investigators participating in clinical study drug/device trials to 
maintain detailed clinical data for one of the following periods: 
ÔÇ∑At least two years following the date on which a New Drug Application is approved
by the FDA, or
ÔÇ∑Two years after the Sponsor notifies the investigator that no further application is to
be filed with the FDA.
Similarly, current EU Directives / Regulations and ICH guidelines collectively require that 
essential clinical trial documents (including case report forms) other than subject‚Äôs medical files 
must be retained for the following time period: 
ÔÇ∑‚Äî for at least 15 years after completion or discontinuation of the trial,
ÔÇ∑‚Äî or for at least two years after the granting of the last marketing authorisation in the
Europea
n Community and when there are no pending or contemplated marketing
applications in the European Community,
ÔÇ∑‚Äî or for at least two years after formal discontinuation of clinical development of the
study dru
g/device.
Subject's medical files should be retained in accordance with applicable legislation and in 
accordance with the maximum period of time permitted by the hospital, institution or private 
practice.  The documents can be retained for a longer period, however, if required by the 
applicable regulatory requirements or by agreement with the sponsor.  
To comply with these requirements, the investigator will not dispose of any records relevant to 
this study without either (1) written permission from the Sponsor or (2) providing an opportunity 
for the Sponsor to collect such records.  The investigator shall take responsibility for maintaining 
adequate and accurate hard copy source documents of all observations and data generated during 
this study, including the hard copy or discs received from the sponsor of the final data.  Such 
documentation is subject to inspection by the Sponsor or its agents, the FDA and/or other 
regulatory agencies. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 53 12. QUALI
TY CONTROL AND QUALITY ASSURANCE
12.1. Monitoring 
The Sponsor has ethical, legal and scientific obligations to carefully follow this study in 
accordance with established research principles and applicable regulations.  The investigator, as 
part of his responsibilities, is expected to cooperate with the Sponsor in ensuring that the study 
adheres to the protocol and GCP requirements.   
As part of a concerted effort to fulfill these obligations, the Sponsor's monitor will visit the 
center(s) during the study in accordance with the Monitoring Plan set forth for this trial.  The 
investigator will permit the Sponsor to monitor the study as frequently as is deemed necessary 
and provide access to medical records/source documents to ensure that data are being recorded 
adequately, that data are verifiable and that protocol adherence is satisfactory.   
12.2. Auditing 
The Sponsor may conduct audits at the study center(s).  Audits will include, but not be limited to, 
study drug supply, presence of required documents, the informed consent process, and 
comparison of eCRFs with source documents.  The investigator agrees to permit audits 
conducted at a reasonable time in a reasonable manner. 
Regulatory authorities worldwide may also inspect the investigator during or after the study.  
The investigator should contact the Sponsor immediately if this occurs, and must permit 
regulatory authority inspections. 
12.3. Protocol Deviations 
This study will be conducted as described in this protocol, except for an emergency situation in 
which the protection, safety, and well-being of the subject requires immediate intervention, 
based on the judgment of the investigator (or a responsible, appropriately trained professional 
designated by the investigator). In the event of a significant deviation from the protocol due to an 
emergency, accident, or mistake, the investigator or designee must contact the Sponsor, or their 
agent, at the earliest possible time by telephone. This will allow an early joint decision regarding 
the subject‚Äôs continuation in the study. The investigator and the Sponsor will document this 
decision. The IRB/EC will be informed of all protocol changes by the investigator in accordance 
with the IRB/EC established procedure. No deviations from the protocol of any type will be 
made without complying with all the IRB/EC established procedures. 
The following Protocol Deviations will require additional information in the eCRF explaining 
why the deviation occurred and what will be done to prevent it from re-occurring: 
ÔÇ∑Inclusion criteria violation
ÔÇ∑Exclusion criteria violation
ÔÇ∑Injection not administered for any reason other than subject safety or withdrawal
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 54 ÔÇ∑Wrong dose
 (dose concentration, wrong dose, wrong treatment, wrong regimen,
wrong inje
ction site )*
ÔÇ∑Missed assessment as per the Schedule of Events/Assessments ( Section  6.1) at
Baseline, dosing visits and EOS
ÔÇ∑Subject not
 adhering to protocol subject restrictions
ÔÇ∑Subject taking any prohibited concomitant medication
*If the mis
-dosing was unintended, i.e. a medication error, the error should be reported as per
instructions in Section 8.3.3, Procedure for Medication Error Reporting. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 55 13. ETHICS A
ND RESPONSIBILITY
This study will be conducted in compliance with the protocol, the Sponsor‚Äôs standard operating 
procedures and/or guidelines, the United States Food and Drug Administration (FDA) 
regulations, the International Conference on Harmonization (ICH) GCP guidelines, the 
Declaration of Helsinki and other local regulations, as applicable. 
13.1. Informed Consent 
Written informed consent will be obtained from all subjects (or their guardian or legally 
authorized representative), and whenever possible, verbal assent will be obtained from children 
12 years of age or older, or as per IRB guidelines, before any study-related procedures (including 
any
 pre-treatment procedures) are performed.  The investigator(s) has both ethical and legal 
responsibility to ensure that each subject (and their guardian or legally authorized representative) 
being considered for inclusion in this study is given a full explanation of the protocol.  This shall 
be documente
d on a written informed consent form, which shall be approved by the same IRB or 
EC responsible for approval of this protocol.  Each informed consent form shall include the 
elements required by ICH, Part E6, Section 4.8 and any applicable local regulations.  The 
investigator agrees to obtain approval from the Sponsor of any written informed consent form 
used in the study, preferably prior to submission to the IRB or EC.  
Once the appropriate essential information has been provided to the subject and fully explained 
by the investigators (or a qualified designee) and it is felt that the subject understands the 
implications of participating, the subject and the investigator (or designee) shall sign the IRB- or 
EC-approv
ed written informed consent form.  The subject shall be given a copy of the signed 
informed consent form, and the original shall be filed appropriately, according to the institution.  
A second copy may be filed in the subject's medical record, if allowed by the institution. 
13.2. Institutional Review Board/Ethics Committee 
This protocol, the written informed consent form and any materials presented to subjects shall be 
submitted to the IRB or EC identified with this responsibility.  Notification in writing of 
approval must come from the IRB or EC chairman or secretary, to the investigator, either as a 
letter or as a
 copy of the appropriate section of the IRB or EC meeting minutes where this 
protocol and associated informed consent form were discussed.  The investigator will not 
participate in the decision.  If the investigator is an IRB or EC member, the written approval 
must indicate such non-participation in the voting session.  The investigator will submit status 
reports to the IRB or EC as required by the governing body.  The IRB or EC must be notified by 
the investigator in writing of the interruption and/or completion of the study; the investigator 
must promptly report to the IRB or EC all changes in research (protocol amendments) and will 
not make such changes without IRB or EC approval, except where necessary to eliminate 
apparent immediate hazards to human subjects.  In cases where it is necessary to eliminate 
immediate hazards to subjects, the IRB or EC must then be notified of the change as per local 
requirements.  The investigator is required to maintain an accurate and complete record of all 
written correspondence to and received from the IRB or EC and must agree to share all such 
documents and reports with the Sponsor.  
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 56 14. CONF
IDENTIALITY
All information generated in this study must be considered highly confidential and must not be 
disclosed to any
 persons not directly concerned with the study without written prior permission 
from the Sponsor.  However, authorized regulatory officials and Sponsor personnel will be 
allowed full access to the records.  All medications provided and subject bodily fluids and/or 
other materials collected shall be used solely in accordance with this protocol, unless otherwise 
agreed to in writing by the Sponsor. 
Only unique subject numbers in eCRFs will identify subjects.  Their full names may, however, 
be made known to a product regulatory agency or other authorized official if necessary. 
With respect to the clinical trial data that is received from countries in the European Economic 
Area and Switzerland, MDCO has certified adherence to the US-EU and the US-Swiss Safe 
Harbor Principles.  
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
Protocol Amendment 1  The Medicines Company 
Confidential 57 15. INV
ESTIGATOR AGREEMENT
I have read and understand the protocol (including the Investigator‚Äôs Brochure) and agree that it 
contains all the ethical, legal and scientific information necessary to conduct this study.  I will 
personally conduct the study as described. 
I will provide copies of the protocol to all physicians, nurses and other professional personnel 
responsible to me who will participate in the study. I will discuss the protocol with them to 
assure myself that they are sufficiently informed regarding the new study drug ALN-PCS SC, the 
concurrent medications, the efficacy and safety parameters and the conduct of the study in 
general. I am aware that this protocol must be approved by the Institutional Review Board (IRB) 
or Ethics Committee (EC) responsible for such matters in the Clinical Study Facility where 
ALN-PCS SC will be tested prior to commencement of this study. I agree to adhere strictly to the 
atta
ched protocol.  I understand that this IRB or EC approved protocol will be submitted to 
relevant regulatory authorities by the Sponsor, as appropriate. I agree that clinical data entered on 
case report forms by me and my staff will be utilized by the Sponsor in various ways such as for 
submission to governmental regulatory authorities and/or in combination with clinical data 
gathered from other research sites, whenever applicable. I agree to allow Sponsor monitors and 
auditors full access to all medical records/source documents at the research facility for subjects 
screened or enrolled in the study. 
I agree to provide all subjects with informed consent forms, as required by government and ICH 
regulations. I further agree to report to the Sponsor any adverse experiences in accordance with 
the terms of this protocol, ICH guideline, Part E6, Section 4.11 and applicable local regulations. 
Principal Investigator (Signature)  Date  
Principal Investigator (Printed Name)  Protocol Version: Amendment 1 
(07 November 2016) 
Institution Name  
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 58 16. REFER
ENCES
ALN-TTRSC-001; EudraCT 2012-004203-12. 
ALN
-TTRSC-002; EudraCT 2013-002856-33. 
Abifadel M, Va
rret M, Rab√®s JP, et al, Mutations in PCSK9 cause autosomal dominant 
hypercholesterolemia. Nat Genet . 2003;34(2):154 -6. 
Ashwell
 G and Morell AG, The role of surface carbohydrates in the hepatic recognition and 
transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol . 1974;41(0):99-
128. 
Banerjee Y, Shah K, and Al-Rasadi K. Effect of a monoclonal antibody to PCSK9 on LD L 
cholesterol. N Engl J Med . 2012;366(25):2425-6; author reply: 2426. 
Cholesterol Treatment Trialists‚Äô (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy 
and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 
170,000 participants in 26 randomised trials. Lancet.  2010;376(9753):1670-81.  
Coelho T, Ada
ms D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin 
amyloidosis. N Engl J Med . 2013;369(9): 819-29. 
Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low 
LDL, and protection against coronary heart disease. N Engl J Med . 2006;354(12):1264-72. 
Cuchel M, Bruckert E, Ginsberg HN et al. Homozygous familial hypercholesterolaemia: new 
insights and guidance for clinicians to improve detection and clinical management. A 
position paper fromthe Consensus Panel on Familial Hypercholesterolaemia of the European 
Atherosclerosis Society. European Heart Journal  2014; 35: 2146‚Äì2157. 
Davidson MH, Ma
ki KC, Pearson TA, et al. Results of the National Cholesterol Education 
(NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey 
and implications for treatment under the recent NCEP Writing Group recommendations. Am 
J C
ardiol.  2005;96(4):556-63. 
Dias CS
, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density 
lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, 
ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on 
statins. J Am
 Coll Cardiol.  2012;60(19):1888-98. 
Elbashir SM, Ga
rborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA 
interference in cultured mammalian cells. Nature.  2001;411(6836): 494 -8. 
Foley
 KA, Simpson RJ Jr, Crouse JR 3rd, et al. Effectiveness of statin titration on low -densit y 
lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J 
Cardiol . 2003;92(1):79 -81. 
Foody
 JM, Sajjan SG, Hu XH, et al. Loss of early gains in low-density lipoprotein 
cholesterol goal attainment among high-risk patients. J Clin Lipidol . 2010;4(2):126-32. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 59 Geisbert TW
, Hensley LE, Kagan E, et al. Postexposure protection of guinea pigs against a 
lethal ebola virus challenge is conferred by RNA interference. J Infect Dis . 
2006;193(12):1650 -7. 
Grundy
 SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the 
National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation . 
2004;110(2):227 -39. 
Hooper AJ
, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is 
present and lowers blood cholesterol in a Southern African population. Atherosclerosis.  
2007;193(2):445-8. 
Hooper AJ
 and Burnett JR. Anti-PCSK9 therapies for the treatment of hypercholesterolemia. 
Expert opinion on biological therapy . 2013;13(3):429-35. 
Horton JD, Cohen 
JC, and Hobbs HH. PCSK9: a convertase that coordinates LDL 
catabolism. J Lipid Res . 2009;50 Suppl:S 172-7. 
Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA 
mediating potent gene silencing in vivo. Mol Ther . 2006;13(3):494-505. 
Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 
18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet . 
2008;371(9607):117-25. 
Milazzo L and Antinori S. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. 
N Engl J Med. 2012;366(25):2425; author reply 2426. 
Morrissey DV
, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity 
of chemically modified siRNAs. Nat Biotechnol . 2005;23(8):1002-7. 
Mousavi SA, Berge KE, and Leren TP. The unique role of proprotein convertase 
subtilisin/kexin 9 in cholesterol homeostasis. J Intern Med . 2009;266(6):507 -19. 
Nag S
S, Daniel GW, Bullano MF, et al. LDL -C goal attainme nt among patients newly 
diagnosed with coronary heart disease or diabetes in a commercial HMO. J Manag Care 
Pharm . 2007;13(8):652 -663. 
Raa
l F, Scott R, Somaratne R, et al. Low-Density Lipoprotein Cholesterol-Lowering Effects 
of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 
Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The 
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial 
Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial. Circulation . 
2012;126(20):2408 -17. 
Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of 
dyslipidaemias. The Task Force for the management of dyslipidaemias of the European 
Society of Cardiology (ESC) and the European Athe rosclerosis Society (EAS). EHJ.  
2011;32:1769 ‚Äì1818. 
Roth EM, McKe
nney JM, Hanotin C, et al. Atorvastatin with or without an Antibody to 
PCSK9 in Primary Hypercholesterolemia. N Engl J Med . 2012;367(20):1891-900. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 60 Sampso
n HA, Munoz-Furlong A, Bock SA, et al. Symposium on the definition and 
manage
ment of anaphylaxis: summary report. J Allergy Clin Immunol . 2005;115(3):584 -91. 
Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition 
and manag
ement of anaphylaxis: summary report ‚Äì Second National Institute of Allergy and 
Infe
ctious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin 
Immunol. 2006, 117(2)
:391-7. 
Soutschek J
, Akinc A, Bramlage B, et al., Therapeutic silencing of an endogenous gene by 
systemic administration of modified siRNAs. Nature . 2004;432(7014): 173-8. 
Stein EA, Me
llis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on 
LDL cholesterol. N Engl J Med . 2012;366(12): 1108-18. 
Stone NJ
, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment 
of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the 
American College of Cardiology/American Heart Association Task Force on Practice 
Guidelines. Circulation.  2014;129(suppl 2):S1‚ÄìS45. 
Sulli
van D, Olsson AG, Scott R, et al. Effect of a Monoclonal Antibody to PCSK9 on Low-
Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients: The GAUSS 
Randomized Trial. JAMA . 2012;308(23):2497-506. 
Tabernero J, Shapiro GI, LoRusso, et al. First- in-Humans Trial of an RNA Interference 
Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement. Cancer 
Discov . 2013;3(4):406-417. 
World Health Organization Cardiovascular Statistics, 2011, 
http://www.who.int/mediacentre/factsheets/fs317/en/index.html. 
Yusef S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated 
with myocardial infarction in 52 countries (the INTERHEART study): case-control study. 
Lancet . 2004; 364:937 -952. 
Zhao 
Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss -of-function 
mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet . 
2006;79(3):514 -23. 
Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human 
primates. Nature. 2006;441(7089):111-4. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 61 APP
ENDIX A. NEUROLOGICAL EXAMINATION 
MOTOR FUNCTION 
When assessing motor function, from a neurological perspective, the assessment should focus on 
arm and leg movement. You should consider the following: 
1. Muscle size
2. Muscle tone
3. Muscle strength
4. Involuntary movements
5. Posture, gait
Symmetry is the most important consideration when identifying focal findings. Compare one 
side of the body to the other when performing your assessment. 
Limb assessment of a conscious subject usually involves a grading of strength. 
Grade Strength 
Grade strength Description  
5 Full range of motion against gravity and resistance; normal muscle strength  
4 Full range of motion against gravity and a moderate amount of resistance; slight weakness  
3 Full range of motion against gravity only, moderate muscle weakness  
2 Full range of motion when gravity is eliminated, severe weakness  
1 A weak muscle contraction is palpated, but no movement is noted, very severe  weakness  
0 Complete paralysis  
NB: In a conscious subject, the single best test to quickly identify motor weakness is the ‚Äúdrift 
test‚Äù. Have the subject hold their arms outward at 90 degrees from the body. With palms up, 
have the 
subject close their eyes and hold the arms for a couple of minutes. ‚ÄúDrifting‚Äù will occur 
if one side is wea
k. 
Lower Extremities 
Assess the subject in a supine position. Ask him/her to separate both legs to test for hip 
abducti
on. Then ask the subject to bring the legs back together to test for hip adduction. Sit the 
subjec
t on the side of the bed to assess knee flexion and extension. Ask the subject to flex and 
extend the
 knee. If able to do this, apply resistance as these movements are repeated. Test plantar 
and dorsiflexion by having the subject push down against your hand with their foot and then pull 
up against
 your hand with their foot. Remember to compare the left side to the right side. 
Upper Extremities 
Assess ability to flex elbow (biceps) and straighten (triceps). Assess ability to raise shoulders and 
return to a re
sting position. Assess wrist flexion and extension. Test each function with 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 62 resistanc
e. For focused upper extremity assessment, assess each digit for flexion, extension and 
lateral movement. 
SENSORY FUNCTION 
When assessing sensory function remember that there are three main pathways for sensation and 
they should be compared bilaterally: 
1. Pain and temperature sensation
2. Position sense (proprioception)
3. Light touch
Pain can be assessed using a sterile pin. Light touch can be assessed with a cotton wisp. To test 
proprioception, grasp the subject's index finger from the middle joint and move it side to side and 
up and down. Have the subject identify the direction of movement. Repeat this using the great 
toe. 
Se
nsory Tests: 
A number of tests for lesions of the sensory cortex can be done. Examples include the following: 
ÔÇ∑ÔÄ†Stereognosis : The abil ity to recognize an object by feel. Place a common object in the persons
hand and ask them to identify the object. 
ÔÇ∑ÔÄ†Graphesthesis: ‚ÄúDra w‚Äù a number in the palm of the person‚Äôs hand and ask them to identify the
number. 
ÔÇ∑ÔÄ†Two-Point Discrimination: Simult aneously apply two pin pricks to the skin surface.
Continually repeat the test while bringing the two pins closer together, until the individual can no 
longer identify two separate stimuli. The finger tips are the most sensitive location for 
recognizing two point differences while the upper arms, thighs and back are the least sensitive. 
ÔÇ∑ÔÄ†Extinction: Touch the same spot on both sides of the body at the same time (eg, the left and
right forearms). Ask the individual to describe how many spots are being touched. Normally, 
both sides are felt; with sensory lesions the individual will sense only one. 
ÔÇ∑ÔÄ†Point Locations: Touch the surface of the skin and remove the stimulus quickly. Ask the
individual to touch the spot where the sensation was felt. Sensory lesions can impair accurate 
identification, even if they retain their sensation of light touch. 
TONE and REFLEXES 
Upper motor neuron problems (brain and spinal cord) are associated with increased tone. Lower 
motor neuron problems are associated with decreased tone. 
Look at the muscles on each side of the body in pairs. Assess for symmetry of bulk. 
Evaluation of the stretch reflexes assesses the intactness of the spinal reflex arc at various spinal 
cord levels. The limb should be relaxed while applying a short and snappy blow with a reflex 
hammer. Hold the hammer loosely in a relaxed manner, making a wrist action. Allow the 
hammer to bounce. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 63 Reflex responses:  
0 No response  
1+ Diminished, low normal  
2+ Average, normal  
3+ Brisker than normal  
4+ Very brisk, hyperactive  
Lower motor neuron disease is associated with 0 or 1+, upper motor neuron disease is associated 
with 3+ or 4+. 
Biceps Reflex (C5 ‚Äì C6) 
Support t
he forearm on the examiners forearm. Place your thumb on the bicep tendon (located in 
the front of the bend of the elbow; midline to the anticubital fossa). Tap on your thumb to 
stimulate a response. 
Triceps Reflex (C7-C8) 
Have the individual bend their elbow while pointing their arm downward at 90 degrees. Support 
the upper arm so that the arm hangs loosely and ‚Äúgoes dead‚Äù. Tap on the triceps tendon located 
just above the elbow bend (funny bone). 
Brachioradialis Reflex (C5-C6): 
Hold the person‚Äôs thumb so that the forearm relaxes. Strike the forearm about 2-3 cm above the 
radial styloid process (located along the thumb side of the wrist, about 2-3 cm above the round 
bone at the bend of the wrist). Normally, the forearm with flex and supinate. 
Quadr
iceps Reflex (Knee jerk) L2 ‚Äì L4  
Allow the lower leg
s to dangle freely. Place one hand on the quadriceps. Strike just below the 
knee cap. The lower leg normally will extend and the quadriceps will contract. 
If the subject is supine: Stand on one side of the bed. Place the examiners forearm under the 
thigh c
losest to the examiner, lifting the leg up. Reach under the thigh and place the hand on the 
thigh of the opposite leg, just above the knee cap. Tap the knee closest to the examiner, (the one 
that has been lifted up with the examiners forearm). 
Achilles Reflex (ankle jerks) L5 ‚Äì S2: 
Flex the kne
e and externally rotate the hip. Dorsiflex the foot and strike the Achilles tendon of 
the heel. In conscious subjects, kneeling on a chair can help to relax the foot. 
Heel Lift 
While the subject is supine, bend the knee and support the leg under the thigh. Have the leg ‚Äúgo 
dead‚Äù. B
riskly jerk the leg to lift the heel of the bed. Normally, the leg will remain relaxed and 
the heel will slide upward; increased tone will cause the heel and leg to stiffen and lift off the 
bed. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 64 Babin
ski Response: 
Dorsiflexion of the great toe with fanning of remaining toes is a positive Babinski response. This 
indicates upper motor neuron disease. It is normal in infants. 
CEREBELLAR FUNCTION 
The cerebellum is responsible for muscle coordination and balance on the same side. To test 
cerebellar function use the following tests: 
1. Finger to finger test: have the subject touch their index finger to your index finger (repeat
several times). 
2. Finger to nose test: perform with eyes open and then eyes closed.
3. Tandem walking: heel to toe on a straight line.
4. Romberg test: stand with feet together and arms at their sides. Have subject close his/her eyes
and maintain this position for 10 seconds. If the subject begins to sway, have them open their 
eye
s. If swaying continues, the test is ‚Äúpositive‚Äù or suggestive of cerebellum problems. 
Dizziness that occurs in response to position changes is usually blood pressure initiated. If the 
subject sways during a Romberg test, but stops when the eyes are opened, the problem is 
probably
 visual or CN VIII (vestibular). 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 65 APP
ENDIX B. SAMPSON CRITERIA FOR DIAGNOSING 
ANAPHYLAXIS 
Anaphylaxis is highly likely when any one of the following three criteria is fulfilled: 
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal
tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips-tongue-uvula) 
AND AT LEAST ONE OF THE FOLLOWING: 
a. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced peak
expiratory flow [PEF], hypoxemia) 
b. Reduced blood pressure or associated symptoms of end-organ dysfunction (eg, hypotonia
[collapse], syncope, incontinence) 
2. Two or more of the following that occur rapidly after exposure to a likely allergen for that
subject (minutes to several hours): 
a. I
nvolvement of the skin-mucosal tissue (eg, generalized hives, itch-flush, swollen lips-
tongue-uvula) 
b. Respiratory compromise (eg, dyspnea, wheeze, bronchospasm, stridor, reduced PEF,
hypoxemia 
c. Reduced BP or associated symptoms (eg, hypotonia [collapse], syncope, incontinence)
d. Persistent gastrointestinal symptoms (eg, painful abdominal cramps, vomiting)
3. Reduced blood pressure after exposure to a known allergen for that subject (minutes to several
hours): 
a. Infants and children: low systolic blood pressure (age specific) or > 30% decrease in
systolic blood pressure* 
b. Adults: systolic blood pressure <90 mmHg or >30% decrease from that person‚Äôs baseline
*Low systolic blood pressure for children is age specific and defined as: <70 mmHg for age 1
month to 1 year; <70 mmHg + [2 x age] for age 1 to 10 years; <90 mmHg for age 11 to 17 years. 
Source: Sampson et al, 2005; Sampson et al, 2006. 
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 66 APP
ENDIX C. TLC DIET 
Definition 
Although there are several diets that will result in lowered LDL cholesterol, the National 
Cholesterol Education Program (NCEP) set forth guidelines for medical professionals to follow 
when instructing patients on a medical nutrition option for lowering cholesterol. Termed the TLC 
diet or the Therapeutic Lifestyle Changes Diet it emphasizes heart healthy lifestyle choices. 
The Therapeutic Lifestyle Changes diet (TLC) is a cholesterol lowering diet that refers to a 
cholesterol-lowering treatment that lowers a person‚Äôs low-density lipoprotein (LDL) level and 
raises their high-density lipoprotein (HDL) level enough to reduce their risk of a heart attack or 
other chronic disease caused by hardening of the arteries. 
The TLC diet follows these dietary guidelines 
ÔÇ∑Less than 7% of the day‚Äôs total calories from saturated fat.
ÔÇ∑25-35% of the day‚Äôs total calories from fat.
ÔÇ∑Less t
han 200 milligrams of dietary cholesterol a day.
_________________________________________________________________________ 
TLC diet tips  
Meat, Poultry, Fish, Dry Beans, Eggs, and Nuts  
ÔÇ∑Limit the total amount of meat to 5 ounces or less per day
ÔÇ∑Choose chicken and turkey without skin or remove skin before eating
ÔÇ∑Eat fish, like cod, that has less saturated fat than either chicken or meat
ÔÇ∑Dry pe
as and beans and tofu (bean curd) are great meat substitutes
ÔÇ∑Limit egg yolks to no more than 2 yolks per week, including egg yolks in baked goods
ÔÇ∑Substitute egg whites for whole eggs
Milk, Yogurt, and Cheese  
ÔÇ∑Eat 2 to 3 servings per day of low-fat or nonfat dairy products
ÔÇ∑Choose varieties that have 3 grams of fat or less per ounce, including low-fat (1%) or
nonfat cottage cheese
ÔÇ∑Buy frozen desserts that are lower in saturated fat, like ice milk, low-fat frozen yogurt,
sorbet
ÔÇ∑Try low-fat or nonfat sour cream or cream cheese blends
ALN-PCS SC Clinical Study Protocol MDCO-PCS-16-02
                                Protocol Amendment 1  The Medicines Company 
Confidential 67 Fats and Oi
ls 
ÔÇ∑Replace saturated fats with unsaturated fat and limit the total amount of fats or oils
ÔÇ∑Use liquid vegetable oils that are high in unsaturated fats (canola, corn, olive, peanut,
safflower, sesame, soybean, sunflower oils)
ÔÇ∑Use margarine made with unsaturated liquid vegetable oils as the first ingredient
ÔÇ∑Limit butter, lard, fatback, and solid shortenings
ÔÇ∑Buy light or nonfat mayonnaise and salad dressing
Fruits and Vegetables  
ÔÇ∑Eat at least 3 to 5 servings of fruits and vegetables each day
ÔÇ∑Buy fruits and vegetables to eat as snacks, desserts, salads, side dishes, and main dishes
ÔÇ∑Add a variety of vegetables to meat stews or casseroles or make a vegetarian main dish
ÔÇ∑Snack on raw vegetables (carrots, broccoli, cauliflower, lettuce)
ÔÇ∑Season with herbs, spices, lemon juice, vinegar, fat free or low-fat mayonnaise or salad
dressing
Breads, Cereals, Rice, Pasta, and Other Grains  
ÔÇ∑Eat 6 to 11 servings of foods from this group each day
ÔÇ∑Choose whole grain breads and rolls
ÔÇ∑Buy dry cereals, most are low in fat, and limit high fat granola, muesli, and oat bran types
made with coconut or coconut oil and nuts
ÔÇ∑Buy pasta and rice to use as entrees and eliminate the high fat sauces (butter, cheese,
cream)
ÔÇ∑Limit sweet baked goods that are made with lots of saturated fat
Sweets and Snacks  
ÔÇ∑Choose sweets and snacks only every now-and-then
ÔÇ∑Buy snack foods low in fat
ÔÇ∑Some sweets and snacks may be low in fat, but most are not low in calories
ÔÇ∑To reduce sodium intake, look for low sodium or unsalted varieties
____________________________________________________________________________  
ÔÇ∑Limit sodium intake to 2400 milligrams or less per day.
ÔÇ∑Just enough calories to achieve or maintain a healthy weight and reduce your blood
cholesterol level.
Reference : http://www.diet.com/store/facts/tlc-diet  